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1. Introduction 
 
The prevalence of diabetes mellitus has taken on epidemic proportions and is 
increasing continuously. In 2009, more than 220 million people were diagnosed with 
diabetes worldwide (WHO 2009). It is estimated that approximately 285 million 
people, aged 20-79 years, will be diagnosed with diabetes worldwide in 2010. By 
2030, the figure is expected to rise to 439 million of the adult population (IDF 2006). 
Although great advances have been made in the care of patients with diabetes, it’s 
still long before all patients suffering from diabetes mellitus reach the therapeutic goal 
and long term damages are confined (Kerner 1998). 
In most countries, diabetes is one of the major causes of premature illness and 
death. Over time it leads to serious damage to many of the body's organ systems 
induced by macro- and microvascular disease. Cardiovascular disease causes the 
death of at least 50% of people with diabetes, depending on the population.  
One of the most important sequella in chronic diabetes is diabetic nephropathy. 
When diabetic nephropathy progresses it eventually leads to end stage renal disease 
(ESRD). 26 million American adults suffer from diabetic nephropathy (2010 National 
Kidney Foundation). In Germany, diabetes mellitus is the underlying disease in 23% 
of all patients suffering from ESRD and 34% of patients with renal disease add to this 
list every year (www.bundesverband-niere.de/files/QuaSi-Niere-Bericht_2006-2007). 
To this day, the pathogenesis of diabetic nephropathy hasn’t entirely been 
investigated. 
Understanding the basic biology of diabetes mellitus and associated late 
complications required the adoption of rodent models. The observation of e.g. 
humanized, transgenic or knock-out mouse models provided an important innovation 
in diabetes research. Further, selective inbreeding has produced several animal 
strains that are considered reasonable models of Type 1 and Type 2 diabetes 
mellitus and related phenotypes such as obesity and insulin resistance (Rees and 
Alcolado, 2005). A novel animal model of diabetic kidney disease are transgenic mice 
expressing a dominant negative glucose-dependent insulinotropic polypeptide 
receptor (GIPRdn), which develop kidney lesions that resemble those observed in 
human diabetic patients (Herbach et al., 2009). In addition, necropsy of a GIPRdn 
transgenic mouse by coincidence revealed unilateral renal agenesia. The remaining 
kidney of this animal showed advanced diabetes-associated glomerular and tubulo-
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interstital lesions that were more severe than kidney alterations of GIPRdn transgenic 
animals investigated so far (Wanke and Herbach, personal communication). 
 
In the present study, uninephrectomy was performed in young GIPRdn transgenic 
mice, in order to mimic the situation observed in the animal that exhibited unilateral 
renal agenesia. A precise clinical, pathomorphological and quantitative stereological 
survey was performed in uninephrectomized GIPRdn transgenic mice to characterize 
kidney lesions in comparison to their non-transgenic and sham operated 
counterparts. 
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2. Literature review 
2.1 Diabetes mellitus 
2.1.1 Definition and description of diabetes mellitus 
Diabetes mellitus is defined as a regulatory dysfunction of metabolism, mainly 
characterized by hyperglycemia. The causes of diabetes are multiple whereby both 
genetic and environmental factors play major roles in its etiology. The underlying 
cause of diabetes mellitus may be destruction of the ß-cells of the pancreas leading 
to impaired insulin secretion, diminished effectiveness of insulin on target tissues, or 
both. The deficient action of insulin induces abnormalities of the carbohydrate, fat 
and protein metabolism. Chronic hyperglycemia leads to long-term damage, 
dysfunction and failure of multiple organs, primarily the eyes, kidneys, nervous 
system, heart, brain and peripheral arteries (Kerner 1998). If the metabolic 
abnormality is mild, patients may be asymptomatic, while in the presence of overt 
hyperglycemia, characteristic symptoms, such as thirst, polydipsia, polyuria, and 
weight loss often occur. Diabetic ketoacidosis and the non-ketotic hyperglycemic-
hyperosmolar dehydration-syndrome are acute life-threatening situations, and there 
is an increased mortality associated with diabetes induced cardiovascular and end-
stage renal disease (ESRD). Diabetes mellitus type 1 and type 2 are the most 
common types of diabetes mellitus in humans, whereas gestational diabetes and a 
few other forms of diabetes mellitus play a secondary role. Diabetes mellitus type 1 is 
an insulin dependent condition with its onset usually in childhood or before the age of 
25, as opposed to diabetes mellitus type 2 with its onset after middle age and a 
primarily non insulin dependent disposition. Type 1 diabetes mellitus is characterized 
by destructive lesions of pancreatic cells either by an autoimmune mechanism or of 
unknown cause. Type 2 diabetes is distinguished by combinations of decreased 
insulin secretion and decreased insulin sensitivity (insulin resistance) (Kuzuya et al., 
2002). 
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2.1.2 Diagnosis of diabetes mellitus 
Urine Test 
The Dipstick test is a very simple color test to ascertain the presence of glucose in 
the urine. However, dipstick tests are not confirming enough to use them as a definite 
diagnosing tool. The reasons are for example that the results can be easily 
misinterpreted, other ketonic or aldehydic groups can interfere with the results, and it 
is a quite costly test. Anyhow, this is a quick way of finding out the disease at a 
household level (www.DiabetesMellitus-Information.com, 2006). 
 
Blood tests 
In the absence of a more specific biological marker to define diabetes, venous 
plasma glucose measurement remains the foundation of diagnostic criteria. 
The diagnosis is made on the basis of fasting blood glucose levels. 
If casual plasma glucose concentrations exceed 200 mg/dl, diabetes mellitus is 
diagnosed. Glucose levels above 100 mg/dl require fasting blood glucose tests. If 
fasting glucose concentrations of at least 126 mg/dl are obtained twice, diabetes 
mellitus is diagnosed. Fasting glucose levels between 100 and less than 126 mg/dl 
are referred to as „impaired fasting glucose“ (IFG). When receiving glucose 
concentrations between 90 and 99 mg/dl, the diabetic risk factors should be 
observed (Kerner et al., 2004). 
 
Glucose tolerance test 
With fasting plasma glucose concentrations between 100 and 125 mg/dl, a glucose 
tolerance test is indicated. The oral glucose tolerance test (OGTT) is an important 
instrument for identifying the pre-diabetic metabolic state in humans. After oral intake 
of 75 g glucose, the blood glucose level is determined at intervals of 60 and 120 
minutes. If blood glucose levels exceed 200 mg/dl after 120 minutes, diabetes 
mellitus is diagnosed. Plasma glucose concentrations between 140 and below 200 
mg/dl two hours after glucose intake indicate impaired glucose tolerance (IGT) 
(Kerner et al., 2004). 
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2.1.3 Classification of diabetes mellitus 
Approximately 90% of the people suffering from diabetes mellitus are diagnosed with 
type 2 diabetes. Unlike type 1 diabetes, the onset of type 2 diabetes is usually found 
after middle age (40 years), and more often at age 60 (IDF 2006). 
In 1997, the conventional classification of the different diabetes mellitus types was 
discarded, due to the fact that it did not describe the pathogenetic mechanisms, but 
rather the therapy applied. The ADA introduced a new nosological classification for 
diabetes mellitus, thus, distinguishing type 1 diabetes, type 2 diabetes, other specific 
diabetes types and gestational diabetes (Kerner 1998). 
Table 1 shows the recent nosological classification. 
 
Table 1 Classification of diabetes mellitus 
I. Type 1 diabetes mellitus (destruction of β-cells causing absolute insulin dependency) 
A. immunologic  
B. idiopathic 
 
II. Type 2 diabetes mellitus (Insulin resistance and/ or failure of β-cell secretion) 
 
III. Other forms of diabetes mellitus 
A. Genetic disorders in β-cell function e.g. 
    (chromosome 12, HNF-1 α (formerly MODY 3), chromosome 7, glucokinase  
 (formerly MODY 2), chromosome 20, HNF-4 α (formerly MODY 1), mitochondrial  
 DNA) 
B. Genetic disorders in insulin effect   
    (Type A insulin-resistance, leprechaunism, Rabson-Mendenhall-syndrome,  
 lipatrophic diabetes) 
C. disease of the exocrine pancreas  
     (pancreatitis, trauma/ pancreatectomy, neoplasia, cystic fibrosis, hemo-
 chromatosis, calcifying fibrotic pancreopathy) 
D. Endocrinopathies 
     (acromegaly, Cushing-syndrome, glucagonoma, pheochromocytoma, 
      hyperthyroidism, somatostatinoma, aldosteronoma) 
E. Diabetes-forms induced by medication or chemicals 
     (neuroleptika (in particular Clozapin, Olanzapin), Pentamidin, Niacin,  
 glucocorticoids, hormones of the thyroid, Diazoxid, β-adrenergic agonists,  
 Thiazide, Phenytoin, α-interferon) 
F. Infections 
     (congenital rubella syndrome, cytomegalovirus infection) 
G. Uncommon forms of immunomediated diabetes mellitus 
     („stiff-person“-syndrome, Anti-insulin-receptor-antibody) 
H. Other genetic syndromes, likely to be associated with diabetes mellitus  
     (Down-syndrome, Klinefelter-syndrome, Turner-syndrome, Wolfram-syndrome,  
 Friedreich-ataxia, Laurence-Moon-Biedl-syndrome, Chorea huntington,  
 dystrophia myotonica, porphyria, Prader-Willi-syndrome) 
 
IV. Gestational diabetes 
 
  
11
2.1.4 Epidemiology 
In 2010, it is estimated that 6.6% of adults aged 20-79 years worldwide are 
diagnosed with diabetes mellitus, and this number is continuously rising (IDF 2006). 
The underlying cause of diabetes is to some extent a genetic predisposition. Since 
the genetic distribution hasn’t changed during the years, it is clear that trigger factors 
play a major role in the development of diabetes. These factors include population 
growth, longer life-span, urbanization, unhealthy diet, overweight, obesity, and lack of 
physical exercise. Without a doubt, diabetes is one of the most challenging health 
problems in the 21st century and thus a global burden. Unfortunately, the severity of 
the sequelae is often underrated. In 2006, diabetes was the seventh leading cause of 
death listed on U.S. death certificates, the cause of death predominantly being end 
stage renal disease (ADA 2007). 
 
2.2 Diabetic nephropathy  
Macroscopically, kidneys of diabetic patients are initially enlarged. This enlargement 
is mainly the result of a combination of tubular hypertrophy and hyperplasia and 
interstitial expansion. Diabetic kidneys may also appear normal sized or smaller than 
kidneys of non-diabetic subjects and these small kidneys are firm and exhibit a 
granular surface and subcapsular scars (Bilous 2001, Heptinstall 1991).  
The clinical syndrome termed ’diabetic nephropathy' is characterized by persistent 
albuminuria, early arterial blood pressure elevation, a relentless decline in glomerular 
filtration rate (GFR), and a high risk of cardiovascular morbidity and mortality (Parving 
et al., 2001). Once the clinical manifestations of diabetic nephropathy, including the 
development of persistent microalbuminuria are present, the structural injury in the 
kidneys is often already far advanced. There are a variety of alterations involving the 
kidney, including nodular and diffuse glomerulosclerosis which both can lead to 
chronic renal failure. The process of diabetic nephropathy in type 1 and type 2 
diabetes mellitus is characterized by: increasing microalbuminuria, decreasing 
glomerular filtration rate, and development or increase of hypertension, and other 
diabetic-born illnesses (Hasslacher et al., 2009). 
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Table 2: The stages of diabetic nephropathy – typical findings 
 
Stage Glomerular filtration Albuminuria Blood pressure 
Time course 
(years after 
diagnosis) 
renal hyperfunction Elevated Absent Normal At diagnosis 
clinical latency High normal Absent   
Microalbuminuria 
(insipient nephropathy) 
Within the 
normal range 
20-200 g/min 
(30-300 mg/day) 
rising within or 
above normal 
range 
5-15 
macroalbuminuria or 
persisting proteinuria Decreasing 
>200 g/min 
(>300 mg/day) Increased 10-15 
Renal failure Diminished Massive Increased 15-30 
The five stages of diabetic nephropathy modified from (Mogensen et al., 1995) 
 
2.2.1 Glomerular changes 
The natural course of diabetic renal disease is thought of as a continuum of 
glomerular injury. 
Diabetic nephropathy is divided into four hierarchical glomerular lesions with a 
separate evaluation for degrees of interstitial and vascular involvement.  
The classification of diabetic glomerulosclerosis is as follows: 
Class I, glomerular basement membrane thickening: isolated glomerular basement 
membrane thickening and only mild, nonspecific changes by light microscopy that do 
not meet the criteria of classes II through IV.  
Class II, mesangial expansion mild (IIa) or severe (IIb): glomeruli with mild or severe 
mesangial expansion but without nodular sclerosis (Kimmelstiel-Wilson lesions) or 
global glomerulosclerosis in more than 50% of glomeruli.  
Class III, nodular sclerosis (Kimmelstiel-Wilson lesions): at least one glomerulus with 
nodular increase in mesangial matrix (Kimmelstiel-Wilson) without changes described 
in class IV. 
Class IV, advanced diabetic glomerulosclerosis: more than 50% global 
glomerulosclerosis with other clinical or pathologic evidence that sclerosis is 
attributable to diabetic nephropathy (Tervaert et al., 2010). 
 
The earliest morphological alteration in diabetic nephropathy is expansion of the 
mesangial area. This is caused by an increase in extracellular matrix deposition and 
mesangial cell hypertrophy. There is a highly significant correlation between 
glomerular filtration rate and mesangial expansion. Research has shown that high 
  
13
glucose levels lead to hypertrophy of mesangial cells which is mediated by insulin-
like growth-factor I, among other factors (Wolf 2004). 
The nodular glomerulosclerosis (Kimmelstiel-Wilson lesions) is not as frequently seen 
as diffuse glomerulosclerosis in diabetes. The nodules are generally associated with 
some degree of diffuse glomerulosclerosis. Panglomerular glomerulosclerosis 
(former also called “diffuse” glomerulosclerosis), is characterized by diffuse 
deposition of basement membrane-like material in the mesangium of the entire 
glomerulus (Reddi and Camerini-Davalos 1990). Extracellular accumulation of 
basement membrane components lead to thickening of glomerular and tubular 
basement membrane and increasing of the mesangial matrix. The structural 
alterations of the kidney tissue reach from exudative lesions in glomeruli and 
arterioles to nodular glomerulosclerosis (Wolf 2004).  
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Fig. 1 Diabetic nephropathy in humans modified from: Pathologic classification of 
diabetic nephropathy (Tervaert et al., 2010) 
 (A, B) Class II glomeruli with mild (A) and moderate (B) mesangial expansion. 
 In panel A, the mesangial expansion does not exceed the mean area of a  
 capillary lumen (IIa), whereas in panel B it does (IIb). 
(C, D) In panel D is a class III Kimmelstiel–Wilson lesion.  
 The lesion in panel C is not a convincing Kimmelstiel–Wilson lesion, therefore (on the  
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 basis of the findings in this glomerulus) the finding is consistent with class IIb.  
 For the purpose of the classification, at least one convincing Kimmelstiel–Wilson  
 (as in panel D) needs to be present.  
(E) Panel E is an example of glomerulosclerosis that does not reveal its cause  
 (glomerulus from the same biopsy as panel F). For the purpose of the  
 classification, signs of DN* should be histopathologically or clinically present to  
 classify a biopsy with global glomerulosclerosis in >50% of glomeruli as class IV. 
(F) In panel F, signs of class IV DN* consist of hyalinosis of the glomerular vascular  
 pole and a remnant of a Kimmelstiel–Wilson lesion on the opposite site of the pole.  
  * GBM glomerular basement membrane; * DN diabetic nephropathy 
 
2.2.2 Tubular changes 
The proximal convoluted segment of the tubules in the diabetic kidney often appears 
finely vacuolated, with lipid being demonstrable in frozen sections. In more advanced 
lesions tubular loss, with atrophic tubules showing thickened basement membranes, 
is obvious. Glycogen deposits in the epithelial cells of the pars recta of the proximal 
tubule (Armanni-Ebstein lesions), once considered characteristic for diabetes, are 
recently only occasionally seen (Heptinstall 1991). Furthermore, migration of 
macrophages and other inflammatory cells into the tubulointerstitium sets in (Ziyadeh 
and Wolf 2008). 
 
2.2.3 Interstitial changes 
In more advanced stages of diabetic nephropathy, tubulointerstitial fibrosis sets in 
(http://www.diabetes.versorgungsleitlinien.de). The interstitial space is increased as a 
part of kidney enlargement. Apart from fluid, this space also contains immunologically 
active cells and fibroblasts. These infiltrates often accompany fibrosis of the 
interstitial tissues and are thought to contribute to the fibrogenic process (Bilous 
2001). 
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2.2.4 Proteinuria 
The morphological changes of the human diabetic kidney are the underlying cause of 
functional abnormalities, such as proteinuria, with urinary albumin excretion being the 
most powerful predictor of progression of renal injury (Wang et al., 2000). Proteinuria 
is no longer simply considered a marker for renal dysfunction, protein is nephrotoxic 
and thus damages renal tissue (Marshall and Williams 1998). Albumin becomes 
more toxic to tubular epithelial cells by glycation which explains the great sensitivity 
of the kidney to proteinuria in diabetes mellitus (Ritz 2006). Circulating 
macromolecules have to pass through the endothelial fenestrae, the glomerular 
basement membrane and between podocyte foot processes before appearing in the 
filtrate, and each of these structures provides both a size and an electrostatic barrier 
(Bilous 2001). Dysfunction of the glomerular filter and impaired reabsorption of 
proteins by the epithelial cells of the proximal tubule are two major mechanisms 
responsible for abnormal urinary excretion of proteins (Camici 2005). Different 
studies in patients with diabetes mellitus showed an increase in urinary albumin that 
was above the normal range, but below the level associated with clinical proteinuria 
in many patients (see Table 2). This subclinical increase in urinary albumin is known 
as microalbuminuria. Microalbuminuria is the first detectable clinical abnormality in 
diabetic glomerulopathy. Patients with microalbuminuria are prone to develop 
established nephropathy, which progresses to end-stage renal failure (Newman et 
al., 2005). The great medical interest in detecting microalbuminuria lies in the fact 
that this stage of diabetic nephropathy presents a ‘window of opportunity’: a high 
renal risk is already indicated by the presence of microalbuminuria, while loss of 
glomerular filtration rate (GFR) has not yet occurred (Ritz 1999). An additional 
consequence of overt albuminuria is hypoalbuminemia; this is caused by increased 
urine albumin excretion which leads to a continuous loss of blood proteins. 
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2.3. Animal models 
2.3.1 Animal models of diabetes mellitus and diabetic kidney disease 
Since glomerulosclerosis in diabetic humans is a long term disease and biopsy of the 
kidney is applied only at the onset of clinical signs of nephropathy, the information 
received from human patients is solely on more advanced stages of renal 
dysfunction. Research in this field has leaped forward after Wehner and Petri 
successfully introduced diabetic animal models in 1983 (Wehner 1983). 
Consequently, it was possible to study early stages of diabetic nephropathy. The 
most common animal-models of diabetes mellitus are rodents, in particular mice and 
rats. When the so-called transgenic technology was developed, it was the mouse 
which was found to be of great significance as a laboratory animal (Breyer et al., 
2005, Wogensen et al., 2005). The selection of an animal model for any type of 
human disease calls for a specific model that mirrors the human phenotype and, 
therefore, the clinical suitability of the results. Ideally animal models of diabetes 
should present the clinical situation of the pathogenesis of diabetes and the resulting 
organ specific complications, such as diabetic kidney disease. Transgenic mice 
expressing human genes offer an in vivo model for investigation of pathological 
changes characteristic of diseases in humans (e.g. cells, tissues, immune system) 
without putting patients at risk. Other advantages of the rodent models are their low 
initial and relatively low maintenance cost, the possibility of surveying large numbers 
of animals in a short time, and allowing the study of individuals with precisely known 
ancestry and the ability to set up back-crosses and matings at will. Also, mice are 
easily manipulated genetically, enabling the isolation of the influence of single genes 
(transgenic and knockout mice). On the other hand there are some disadvantages 
with the rodent models, as well. Renal changes in mice don’t resemble those in 
humans exactly, since rodents can’t express the whole clinical picture due to their 
shorter lifespan. Plus, there are differences in the pathologic processes of the rodent 
kidney as opposed to the human kidney (Daneshgari et al., 2009). 
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2.3.1.1 Animal models of type 1 diabetes 
Type 1 diabetes mellitus in humans is characterized by a specific destruction of the 
pancreatic beta cells, commonly associated with immune-mediated damage. 
Although the damage may occur silently over many years, at clinical presentation 
there is little surviving beta cell mass and the disorder progresses to absolute 
insulinopenia. Surgical and toxin-mediated pancreatic damage are valuable tools in 
the study of the consequences of hyperglycemia in laboratory-animals (Rees and 
Alcolado 2005). 
 
Streptozotocin-induced diabetic nephropathy in rats 
Streptozotocin (STZ) is a naturally occurring chemical that is particularly toxic to the 
insulin-producing beta cells of the pancreas in mammals and was originally identified 
in the late 1950s as an antibiotic. Streptozotocin-induced pancreatic injury is 
commonly used for creating rodent models of type 1 diabetes which develop renal 
injury with similarities to human diabetic nephropathy. This model can be established 
in genetically modified rodents for investigating the role of molecular mechanisms 
and genetic susceptibility in the development of diabetic nephropathy (Tesch and 
Allen 2007). If administered in a single large dose, streptozotocin can produce 
diabetes in rodents, probably as a result of direct toxic effects. Alternatively, if 
multiple small doses of streptozotocin are used (e.g. 40 mg/kg on five consecutive 
days), this induces an insulinopenic diabetes in susceptible rodents provoked by 
immune destruction of beta cells, as in human type 1 diabetes. The downside of this 
method is the risk of the development of kidney tumors (Rees and Alcolado 2005), 
and interpreting results in this model may be complicated by nonspecific toxicity of 
STZ (Breyer et al., 2005). 
 
Non-obese diabetic mouse (NOD) 
The non-obese diabetic mouse spontaneously develops insulin dependent diabetes 
mellitus, similar to the illness seen in humans. Insulitis is present when the mice are 4 
to 5 weeks old, followed by subclinical beta cell destruction and decreasing 
circulating insulin concentrations. The pancreatic islets are subjected to an immune 
attack. Unlike human type 1 diabetes, ketoacidosis is relatively mild. Since these 
animals have been inbred in laboratories for many generations, many genes and 
phenotypes will have been enriched, but not all will be relevant to the 
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pathophysiology of diabetes, either in rodents or in humans (Rees and Alcolado 
2005). Disadvantages of the NOD mouse are the unpredictability of the timing of the 
development of diabetes, and that the NOD mice need insulin therapy to survive long 
periods (Breyer et al., 2005). 
 
Bio breeding rat (BB) 
Development of type 1 diabetes mellitus in the BB rat is associated with features that 
are shared with human type 1 diabetes mellitus. Disease onset, for example, is 
preceded by destruction of the insulin-producing beta cells of the pancreas by the 
immune system, and is controlled by many quantitative trait loci. The BB rat shows 
hyperglycemia and vascular complications arising from suboptimal control of blood 
glucose levels (Yang and Santamaria 2006). In these diabetic rats, weight loss, 
polyuria, polydipsia, hyperglycaemia and insulinopenia develop at around 12 weeks 
of age. In common with the human disease, ketoacidosis is severe and fatal unless 
exogenous insulin is administered (Rees and Alcolado 2005). 
 
Long Evans Tokushima lean rat (LETL) 
Diabetes mellitus in Long-Evans Tokushima Lean (LETL) rats closely resembles type 
1 diabetes in humans, although the prevalence of diabetes is only approximately 
20% in these rats. Two sub-strains from the original inbred LETL rat were 
established, a diabetes-prone (KDP) and a non-diabetic (KND) strain. The features of 
KDP rats are a high incidence of diabetes (over all approximately 70%) (Komeda et 
al., 1998). 
 
New Zealand white rabbit 
Through successive inbreeding a colony of rabbits was developed showing a 
spontaneous onset of diabetes mellitus. The diabetic animals are not obese. Despite 
marked increases in serum and urinary glucose, only mild ketonemia is observed 
(Roth and Conaway 1982). 
 
Keeshond dog 
The Keeshond dog comes from a line of dogs with an inherited condition causing 
them to become spontaneously diabetic at the age of 2-6 months, but not obese. 
Aplasia of beta cells of the islet of Langerhans is evident at birth and causes 
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insulinopenia. Persisting solitary β-cells produce sufficient insulin to maintain growth 
until the body's insulin requirement exceeds insulin produced, and the onset of 
diabetes mellitus occurs (Kramer 1981). 
 
Chinese hamster 
Inbred lines of the Chinese hamster develop an insulin-deficient, nonobese form of 
diabetes mellitus type 1 (Kempe et al., 1993). There are six inbred sublines of 
Chinese hamsters that have greater than 85% incidence of glucosuria. At birth, 
hamsters from inbred sublines are considered prediabetic, later on they develop 
diabetes ranging from mild to severe. Morphologic changes have been observed in 
pancreatic islets, kidney, nerve, blood vessels, eyes, brain, and genito-urinary 
systems of diabetic Chinese hamsters. Pathogenesis of diabetes mellitus in this 
animal appears to be related to an increased demand for insulin. Initially there is a 
positive response to this demand by beta cells, but exhaustion occurs. This is 
followed by a decrease in beta cell mass and relative or absolute insulin deficiency 
(Gerritsen 1982). The diabetic Chinese hamster may be a valuable experimental 
model for studying the metabolic abnormalities of a genetic diabetic syndrome not 
easily measured in humans in vivo (Frankel et al., 1974). 
 
2.3.1.2 Animal models of type 2 diabetes 
Type 2 diabetes represents a heterogeneous group of medical conditions 
characterized by insulin resistance and impaired insulin secretion and defined by a 
raised fasting or post-challenge blood glucose. But, for many patients with diabetes 
mellitus type 2, several genetic and environmental factors contribute to the origin and 
progression of the disease and the late complications. Animal models of type 2 
diabetes are likely to be as complex and heterogeneous as the human condition. 
However, many of the strains used today have been generated by selective 
inbreeding of animals that spontaneously develop a type 2 diabetes-like phenotype. 
Studying these different animal models may help explain why some people with 
pathological obesity never develop type 2 diabetes whilst others become 
hyperglycemic at relatively moderate levels of insulin resistance and obesity (Rees 
and Alcolado 2005). 
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Goto Kakisaki rat (GK) 
The Goto Kakisaki rat is a genetic model of type 2 diabetes mellitus. Mildly glucose-
intolerant Wistar rats were selectively inbred to achieve this rat model. The adult GK 
rat displays decreased beta cell mass together with mild hyperglycemia, glucose 
intolerance, impaired glucose-induced insulin secretion, hepatic glucose 
overproduction, and moderate insulin resistance. Impaired development of the GK rat 
pancreas probably results from insufficiency of extra-pancreatic factors necessary for 
the growth and survival of fetal pancreatic cells (Miralles and Portha 2001). The 
fasting blood glucose is only mildly elevated but rises further when glucose is 
administered. The complications of diabetes seen in humans can be compared with 
some features represented by the GK rat. These include renal lesions, structural 
changes in peripheral nerves and abnormalities of the retina. Research into these 
phenomena demonstrates another example of how animal experimentation gives 
way to fields that could not be easily studied in human beings (Rees and Alcolado 
2005) 
 
Kuo Kondo mouse (KK) 
The KK mouse gradually becomes obese in adult life. Restriction of energy intake 
reduces both obesity and hyperglycemia seen in this mouse. Hypertrophy and 
degranulation of pancreatic islet-cells are observed in KK mice. The kidneys of these 
mice show typical changes of diabetic nephropathy such as diffuse and nodular 
glomerulosclerosis, and peripheral glomerular basement membrane thickening in 
addition to mesangial enlargement and hypercellularity. Proteinuria and 
microalbuminuria are also seen in this mouse strain. Therefore, the KK mouse serves 
as a good model for investigating obesity-associated diabetes mellitus in man (Ikeda 
1994). 
 
Nagoya–Shibata–Yasuda mouse (NSY) 
NSY mice spontaneously develop diabetes in an age-dependent manner. Key 
features include impaired insulin secretion and mild insulin resistance. Obesity and 
extreme hyperinsulinemia are not commonly seen in these animals. Interestingly, 
almost all males develop hyperglycemia, but less than a third of females are affected. 
The NSY mouse is particularly useful when considering age-related phenotypes of 
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type 2 diabetes mellitus and for investigating the pathogenesis and genetic 
predisposition to the non-insulin dependant diabetes type (Ueda et al., 1995). 
 
Otsuka Long-Evans Tokushima fatty rat (OLETF) 
The OLETF rat can be traced back to an outbred colony of Long-Evans rats 
selectively bred for glucose intolerance. The characteristic features of OLETF rats 
are the late onset of hyperglycemia (after 18 weeks of age), the chronic course of the 
disease, the mild obesity, the clinical onset of diabetes mellitus mostly seen in males, 
and the hereditary trait. The changes of pancreatic islets proceed to a pathological 
stage showing, among others, atrophy of the islets. Diabetic nephropathy as seen in 
these rats, is demonstrated by diffuse glomerulosclerosis, and nodular lesions. These 
clinical and pathologic features of this illness in OLETF rats resemble those of human 
type 2 diabetes mellitus (Kawano et al., 1994). 
 
Israeli sand rat (Psammomys obesus) 
Originally, the Israeli sand rat feeds on a low-caloric-vegetarian diet. If, under 
laboratory conditions, fed a laboratory chow, the rats develop an obese diabetic 
syndrome with hyperinsulinemia, hyperglycemia, markedly decreased glucose 
tolerance, and insulin resistance, with its onset at thee months of age and forward. 
The hyperglycemic state is associated with an increase in circulating proinsulin and 
split products supposedly being caused by the high demand for insulin secretion due 
to insulin resistance, similar to human type 2 diabetes mellitus. Impaired insulin 
biosynthesis within the islets has also been reported. This rat model is particularly 
useful when investigating the effects of diet and exercise on the development of 
type 2 diabetes mellitus in humans (Marquie et al., 1984, Rees and Alcolado, 2005) .  
 
Ob/ob mouse 
The ob/ob mouse is a monogenic model of obesity, carrying a mutation in the leptin 
gene, the ligand for the leptin receptor, provoking leptin deficiency. Animal models of 
obesity have been used in an attempt to gain insights into the human condition. But 
since the mutation of leptin is a very rare cause of obesity and type 2 diabetes in 
humans, the ob/ob mouse serves only as a poor model for the research in human 
diabetes mellitus type 2 (Breyer et al., 2005).  
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Zucker diabetic fatty rat (ZDF; fa/fa) 
The Zucker diabetic fatty rat, derived from inbreeding of hyperglycemic Zucker obese 
rats, is characterized by a mutation in the leptin receptor leading to high circulating 
leptin levels (Schmidt et al., 2003). The progression to diabetes mellitus in ZDF rats 
is due to a failure to increase beta cell mass in the pancreas, whereas human type 2 
diabetes results from increased pancreatic islet amyloid formation. It is also reported 
that in the ZDF rat model of type 2 diabetes mellitus there is a significant incidence of 
hydronephrosis. Hydronephrosis is characterized by the dilation of the renal pelvis, 
compression of the papilla, and atrophy of the renal parenchyma; these features bear 
no relationship to diabetic nephropathy. This raises serious questions regarding the 
validity of the ZDF rat as a model for studying the renal consequence of diabetes 
mellitus in man (Marsh et al., 2009). 
 
db/db mouse 
The diabetic gene (db) is transmitted in an autosomal recessive manner. The db 
gene encodes for a point mutation of the leptin receptor, leading to abnormal splicing 
and defective signaling of the adipocyte-derived hormone leptin. Lack of leptin 
signaling in the hypothalamus will lead to persistent hyperphagia and obesity with 
consequently high leptin and insulin levels. Hyperinsulinemia in db/db mice is obvious 
at 10 days of age and blood glucose levels are slightly elevated at 1 month of age. 
After 5 to 6 months of age, the body weight and insulin levels begin to fall in 
association with pancreatic islet-cell degeneration, thus rapidly increasing 
hyperglycemia sets in as the remaining beta cells are unable to maintain the high 
levels of insulin secretion required. The db/db mouse also has a long history as a 
model of human diabetic nephropathy. Key common features with the human 
condition are renal hypertrophy, glomerular enlargement, albuminuria, and mesangial 
matrix expansion. Because this model appears to exhibit the most consistent and 
robust increase in albuminuria and mesangial matrix expansion, it has been used as 
a model of progressive diabetic renal disease (Sharma et al., 2003). 
 
Fat-fed streptozotocin-treated rat (fat-fed/STZ rat) 
The fat-fed/STZ rat originates from a non-obese, outbred rat strain of type 2 diabetes 
mellitus that replicates the prevalent background and metabolic characteristics of the 
human metabolic syndrome. Sprague-Dawley rats are fed a high-fat diet (40% of 
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calories as fat) for two weeks and then injected with low-dose streptozotocin. Fat-
fed/STZ rats provide a feasible animal model for type 2 diabetes, simulating the 
human syndrome. This mouse model is suitable for the testing of anti-diabetic 
therapies (Reed et al., 2000). 
 
CBA/Ca mouse 
The CBA mouse was developed by crossing the Bagg albino with the DBA (Dilute 
Brown Non-Agouti) mouse. When brought to Great Britain by Carter, it was renamed 
CBA/Ca (Rithidech et al., 1999). Mature male CBA/Ca mice develop a spontaneous 
mild diabetes-obesity syndrome resembling human type 2 diabetes mellitus. This is 
characterized by hyperglycemia, hyperinsulinemia and insulin resistance. The 
pancreas of mature obese mice possesses significantly enlarged islets. Pancreatic 
beta cells do not degenerate and circulating insulin levels remain high throughout life. 
The mature male CBA/Ca mouse serves as a valuable model for investigating the 
etiology of type 2 diabetes mellitus (Figueroa and Taberner 1994). 
 
Spontaneously Diabetic Torii (SDT) rat  
Clinical characteristics of the SDT rats are hyperglycemia and hypoinsulinemia (from 
25 weeks of age); long-term survival without insulin treatment, and 
hypertriglyceridemia (by 35 weeks of age). This rat model resembles human non-
obese severe type 2 diabetes mellitus with insulin hyposecretion. The SDT rat is 
considered to be a potentially useful model for studies of diabetic retinopathy 
encountered in humans (Shinohara et al., 2000). 
 
New Zealand obese (NZO) mouse 
The NZO mouse has a polygenic syndrome that resembles human metabolic 
syndrome, with hyperphagia, obesity and insulin resistance, associated with 
hyperinsulinemia, hyperglycemia, hypercholesterolemia, and hyperleptinemia. This 
mouse model develops obesity and its related complications, leading to micro- and 
macrovascular injury, atherosclerosis, diabetes, hypertension and pathological 
angiogenesis (Balwierz et al., 2009). 
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Tsumura Suzuki Obese Diabetes (TSOD) mouse 
The TSOD mouse is a relatively new polygenetic model of spontaneous type 2 
diabetes mellitus, established as an inbred line in 1992 (Suzuki et al., 1999). Male 
TSOD mice show severe obesity, hyperglycemia, glucosuria, hyperinsulinemia, 
hyperlipidemia, including high density lipoprotein (HDL)-cholesterol, and abnormality 
of the pancreas and kidney. The TSOD mouse is a good model for studying diabetes-
induced dysfunction of the kidney and pancreas (Kawada et al., 2010). 
 
2.3.1.3 Animal models of diabetic kidney disease 
Diabetic nephropathy in humans is a major complication of diabetes mellitus. It is a 
progressive disease that leads to end-stage renal failure, which requires renal 
replacement therapy such as dialysis or renal transplantation. Late stage diabetic 
nephropathy is characterized by severe glomerulosclerosis, reduced GFR, interstitial 
immune cell infiltrates, tubular atrophy, and interstitial fibrosis. In order to develop 
more effective therapies for these sequelae, the pathophysiological mechanisms of 
this illness need to be clarified in more detail. For this purpose, it is necessary to 
carry out medical science studies in animal models. 
 
KK-Ay mouse 
The KK- Ay mouse is a model of type 2 diabetes mellitus. It was produced by 
transferring the yellow obese gene (Ay allele) into the KK (Kuo Kondo) mouse. The 
diabetic nephropathy phenotypes in this mouse model are more severe than those in 
the original KK mouse. Also, the pathologic kidney findings in the KK- Ay mouse 
resemble those in humans, both immunohistochemically and pathologically. 
Histopathologic alterations in the kidneys of KK-Ay mice are, among others, gradual 
progression of glomerular damage with age, expansion of mesangial matrices, 
nodular lesions, and tubulointerstitial damage. (Yabuki et al., 2010). 
 
Diabetic eNOS knockout mice  
Nitric oxide (NO) is an endothelial cell-derived vasodilator which is an important 
modulator of permeability in the vasculature. In diabetes, the vascular endothelial NO 
synthase (eNOS) activity is altered and the functionally significant polymorphisms in 
the NOS3 gene lead to lower production of NO. This is associated with the 
development of advanced nephropathy in patients with type 1 and type 2 diabetes. 
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Targeting of Nos3, the gene encoding eNOS, induces nephropathic changes in 
mouse models of both type 1 (streptozotocin induced) and type 2 (db/db mouse) 
diabetes that mimic many aspects of human disease. Systemic depletion of eNOS on 
a diabetic background allows the study of both vascular and renal pathology in the 
same animal. Moreover, eNOS knockout mice on a db/db background can readily be 
used to evaluate the efficacy of drug therapy to target multiple-organ pathologies 
(Mohan et al., 2008). A model of type 1 diabetes with deficient eNOS activity was 
produced by inducing diabetes by low-dosage streptozotocin (STZ) injection in eNOS 
deficient mice. These diabetic eNOS mice develop significant increases in mesangial 
expansion, mesangiolysis, and focal sclerosis. Type 2 diabetic eNOS deficient db/db 
mice develop significant albuminuria, decreased glomerular filtration rate, mesangial 
expansion, glomerular basement membrane thickening, arteriolar hyalinosis, 
mesangiolysis, nodular glomerulosclerosis, and tubulointerstitial injury that is 
significantly greater than that found in the low-dosage STZ diabetic eNOS knockout 
mice (Brosius et al., 2009). 
 
Bradykinin B2 Receptor (B2R) deficient Ins2Akita/+ mouse 
The targeted deletion of the bradykinin 2 receptor contributed to the evolution of 
diabetic nephropathy in Ins2Akita/+ mice on a B6 background. This mouse model 
showed a four-fold increase in albuminuria and profound mesangial expansion that 
resembles the glomerular changes seen in human diabetic glomerulosclerosis. There 
are no changes in the glomerular endothelial cells or podocytes. The mice also 
develop mitochondrial DNA damage in the kidneys and other tissues, indicating 
generalized aging (Kakoki et al., 2004). In contrast, Akita mice with functional B1 and/ 
or B2 receptors are not considered a robust model of nephropathy (Brosius et al., 
2009). 
 
Decorin deficient streptozotocin diabetic mouse 
Decorin is a small, leucine-rich proteoglycan that is primarily secreted and stored in 
the extracellular matrix. Decorin can inhibit transforming growth factor beta (TGF-ß) 
activation by binding to the active form of TGF-ß. TGF-ß is a profibrotic cytokine 
involved in the pathogenesis of diabetic renal disease. Decorin is constantly 
stimulated in diabetic nephropathy. The decorin null mouse on a B6 background 
develops enhanced features of nephropathy. Decorin deficiency substantially 
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worsens the progression of diabetic kidney disease in streptozotocin diabetic mice, 
with features that closely mimic advanced human diabetic nephropathy. Diabetic 
mice with decorin deficiency have increased albuminuria, impaired renal function, 
and an increased degree of mesangial matrix expansion with fibrin caps and 
macrophage infiltration. These results conclusively identify decorin as a protective 
agent in this murine model of diabetic nephropathy (Williams et al., 2007). 
 
NONcNZO mouse 
The NONcNZO mouse model is an inbred congenic strain derived from a cross 
between the Nonobese Nondiabetic (NON) mouse and the New Zealand Obese 
(NZO) mouse, which provides a model of polygenic type 2 diabetes. Unlike mice with 
null mutations in a single gene producing morbid obesity, this mouse model develops 
milder obesity produced by the interaction of numerous genes with relatively small 
effects (Leiter and Reifsnyder 2004). After approximately 8 months of age, 
NONcNZO mice develop significant and progressively increasing albuminuria. 
Glomerular histopathology is impressively abnormal but, in addition to 
glomerulosclerosis, exhibits features that are atypical for diabetic nephropathy 
(Brosius et al., 2009). 
 
OVE26 mouse 
The OVE26 mouse (overexpression) is a transgenic model of early-onset type 1 
diabetes. These mice develop diabetes within the first weeks of life as a result of beta 
cell toxicity in response to overexpression of the calmodulin gene under the control of 
the insulin promoter. However, a low level of beta cell survival allows OVE26 
heterozygotes to live and maintain their body weight well over 1 year with no insulin 
treatment. Progressively increasing albuminuria occurs at 9 months of age in 
conjunction with hypalbuminemia, high blood pressure, and decreasing GFR. These 
mice develop progressively enlarged glomeruli, with diffuse and nodular expansion of 
mesangial matrix, tubulointerstitial fibrosis, and thickening of the glomerular 
basement membrane. This model is useful for better understanding and treatment of 
diabetic nephropathy (Zheng et al., 2004). 
 
  
28
Black and tan, brachyuric (BTBR) ob/ob mouse 
BTBR ob/ob mice develop a variety of abnormalities that closely resemble advanced 
human diabetic nephropathy more rapidly than most other murine models. The BTBR 
mouse strain with the ob/ob leptin-deficiency mutation develops severe type 2 
diabetes, hypercholesterolemia, elevated triglycerides, and insulin resistance. These 
obese, diabetic mice briskly reveal morphologic renal lesions characteristic of both 
early and advanced human diabetic nephropathy. Also a persisting, early onset loss 
of podocytes is present. The BTBR ob/ob mouse strain is suggested to be particularly 
interesting for testing therapeutic interventions for diabetic kidney disease (Hudkins 
et al., 2010). 
 
2.3.2 GIPRdn transgenic mice 
This transgenic diabetic mouse model expresses a dominant negative GIP (glucose-
dependent insulinotropic polypeptide) receptor (GIPRdn) in pancreatic beta cells, 
leading to the development of severe early onset diabetes mellitus. GIP is an incretin 
hormone, which is released after food intake from the small intestine. GIP produces 
multiple physiological effects, including increase in glucose-mediated insulin 
secretion, insulin gene transcription, and may act as a mitotic and anti-apoptotic 
agent in pancreatic beta cells. In order to illustrate the role of the GIP receptor within 
the enteroinsular axis in vivo, the expression of a dominant negative mutant of the 
GIPR in transgenic mice was implemented. The cDNA of the human GIPR was 
mutated at the third intracellular loop by a deletion of eight amino acids (positions 
319 to 326) and a point mutation a position 340. The malfunction of this mutated 
GIPR was demonstrated in vitro. Transgenic mice were then generated, expressing 
the mutated human GIPR cDNA under the control of the rat pro-insulin 2 gene 
promoter in pancreatic beta cells. These GIPRdn transgenic mice show an early 
disturbance in pancreatic islet development seen in highly reduced beta-cell mass, 
disturbed composition of islets, and decreased islet neogenesis (Herbach et al., 
2005). Furthermore, decreased insulin secretion and early onset diabetes mellitus, 
without obesity or insulin resistance are evident (Herbach et al., 2008). GIPRdn 
transgenic mice display glucosuria between 14 and 21 days of age. By the age of 30 
days, the blood glucose levels of transgenic mice are largely elevated and an 
absolute insulin deficiency is observed (Herbach et al., 2005). Development, 
dimensions and histological patterns of kidney lesions detected in GIPRdn transgenic 
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mice show similarities to diabetes-associated kidney injury of humans, consequently 
making GIPRdn transgenic mice a promising animal model for studying the onset and 
progression of diabetic nephropathy (Herbach et al., 2009). 
 
2.3.3 Remnant kidney animal models  
It remains difficult to address the progression of kidney lesions in animal models, 
since advanced diabetic nephropathy develops over more than a decade in humans. 
As a matter of fact, all commonly used rodent models of diabetic nephropathy don’t 
display significant tubulointerstitial lesions during a period of 6 months. Experimental 
means that intend to accelerate the development of end-stage kidney disease in 
mice should enhance crucial pathomechanisms of diabetic nephropathy (Ninichuk et 
al., 2007). In scientific animal studies, chronic renal failure is mostly achieved by 
partial removal of renal parenchyma. The two most common techniques used are 
infarction and subtotal nephrectomy (remnant kidney model). The remnant kidney 
model may be achieved by either ligation of renal vessels supplying the renal poles 
or surgical excision of both renal poles followed by contralateral nephrectomy (Liu et 
al., 2003). 
Since the first publication of a remnant kidney model in 1889, numerous investigators 
studied kidney disease by surgically reducing the kidney mass by ½, ⅔ or ¾ in 
various animal species. In 1932 the 5/6 nephrectomy (5/6Nx) rat model which has 
been used ever since was developed (Chanutin and Ferris 1932). Another way of 
producing experimental renal failure is the administration of nephrotoxic agents. 
Nephrotoxic drugs exert a lot of undesirable side-effects including cardiotoxicity 
(Sviglerova et al., 2010). 
 
5/6 surgical nephrectomy in rats  
In Wistar male rats chronic renal failure is induced by 5/6 surgical nephrectomy. This 
is achieved by unilateral nephrectomy plus either surgical ablation of 2/3 of the other 
kidney or selective ligation of extrarenal branches of the left renal artery such that 
approximately 2/3 of the left kidney is infarcted. This model closely resembles chronic 
renal failure in humans, including cardiovascular complications, it shows a high 
degree of reproducibility and a minimum of undesirable side-effects. Thus, the 
present rat model of subtotal surgical renal mass reduction represents a useful tool in 
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the study of chronic renal failure and its cardiovascular complications (Sviglerova et 
al., 2010).  
 
3/4 surgical nephrectomy in rabbits 
The rabbits underwent bipolar left nephrectomy and complete removal of the right 
kidney. Four weeks after nephrectomy, a loss of 75% of the left renal mass is 
confirmed. The animals developed chronic renal failure, and an increase in size of 
the left kidney remnant can be seen at 16 weeks of age. Histological evaluation 
showed subcapsular and interstitial fibrosis and also tubular regeneration. This model 
of chronic renal failure was suggested to be valuable for testing different approaches 
to repair kidney damage (Costa et al., 2009). 
 
Uninephrectomy in db/db mice  
At 24 weeks of age, uninephrectomized db/db mice reveal increased albuminuria and 
severe glomerulosclerosis in 37% of glomeruli as compared to sham-operated 
controls. Uninephrectomy also increases the number of glomerular macrophages in 
db/db mice. The uninephrectomy-related acceleration of glomerular damage is 
associated with significant tubulointerstitial injury as indicated by an increase in 
indices of tubular cell damage, tubular dilatation, and expansion of interstitial volume. 
Uninephrectomy may be a preferred method of accelerating diabetic nephropathy in 
db/db mice because it does not affect unrelated or other pathomechanisms of this 
disease (Ninichuk et al., 2007). 
 
Uninephrectomy in mice treated with VEGF 
Vascular endothelial growth factor (VEGF) is essential for normal renal development 
and plays a role in diabetic glomerular enlargement. Unilateral nephrectomized mice 
treated with VEGF-Antibody show suppressed glomerular enlargement and partially 
blocked renal growth without affecting body weight or food consumption. 
Uninephrectomized mice that did not receive VEGF-Antibody display an increase in 
glomerular volume and kidney weight. These findings indicate that VEGF plays a 
major role in the glomerular compensatory response after uninephrectomy (Flyvbjerg 
et al., 2002). 
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3. Research design and methods 
3.1 Animals 
All animal experiments were performed in accordance with institutionally approved 
and recent animal care guidelines underlying the German animal welfare bill (BGBI I 
p. 1105), AZ 55.2-1-54-2531-100-06. 
Mice investigated in this study were exclusively male heterozygous transgenic mice 
that express a dominant-negative glucose dependent insulinotropic polypeptide 
receptor (GIPRdn) and age-matched non-transgenic littermate controls. The animals 
received a standard breeding diet (Altromin 1324, Germany) and tap water ad libitum. 
They were maintained on a 12 h- light and 12 h- darkness cycle. Mice were weaned 
at 3 weeks p.p., separated according to gender, marked by piercing of the ears, and 
tail tip biopsies for genotype analyses were taken. The chosen male animals 
undertook surgery, i.e. uninephrectomy or sham operation, at 1 month of age. In the 
course of this study, urine samples of each mouse were taken in monthly intervals 
and body weights were recorded biweekly. Animals were euthanized at 6 or 12 
months of age.  
 
3.1.1. Genotyping 
Transgenic mice were identified by polymerase chain reaction as described as 
follows, using DNA extracted from tail tips, according to standard protocols (Herbach 
et al., 2005, Hoeflich et al., 2001). 
 
3.1.1.1 Primers 
For the identification of GIPRdn transgenic mice, oligonucleotide primers with the 
following sequence were used: 
-5'- ACA GNN TCT NAG GGG CAG ACG NCG GG-3' sense (Tra1) 
-5'- CCA GCA GNC NTA CAT ATC GAA GG-3' antisense (Tra3) 
(Synthese, LMU, Munich, Germany) 
These primers bind to the human cDNA of the mutated GIP receptor and also to the 
endogenous murine GIP receptor. The primers were chosen from areas where the 
known DNA sequence of the human, rat, mouse and hamster GIP receptor is highly 
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conserved. Wherever the sequence varies in these animals, oligonucleotide 
synthesis was performed to allow all nucleotides ("N" in primer sequence) to integrate 
(Herbach et al., 2005, Volz, 1997). The mutated human GIP receptor and the 
endogenous murine receptor can be distinguished in the PCR by their number of 
base pairs. The PCR product of the murine GIP receptor contains about 500 base 
pairs, whereas the PCR-product of the mutated human GIP receptors consists of 
about 140 base pairs.  
3.1.1.2 DNA isolation 
At weaning of mice, tail tip biopsies were taken and stored at -20°C until assayed. 
For DNA extraction, a tail tip of approximately 0.5 cm length was incubated in 400 µl 
Mastermix over night in a heating block (Biometra TB1 Thermoblock, Whatman, 
Germany) at 55°C. Thereafter, undigested components were separated by 
centrifugation for two minutes at 15,000 rpm (Sigma 1K15, Sigma, Germany). The 
supernatant was poured into another tube (Eppendorf safe lock tube, Eppendorf AG, 
Germany) and 400 µl isopropanol (Roth, Germany) were added to precipitate DNA. 
The DNA pellet was washed twice with 900 µl 70% ethanol (Roth, Germany), the 
liquid phase was discarded and the DNA pellet was dried at room temperature. DNA 
was suspended in 100 – 200 µl 1xTE buffer, according to the size of the pellet when 
dried. To make sure that the DNA was dissolved completely it was stored at 4°C for 
at least 24 hours before proceeding with the PCR. 
 
Mastermix  
Cutting buffer 375 µl  
SDS 20% (Sodiumdodecylsulfate Ultra Pure, Roth, Germany) 20 µl 
Proteinase K (20mg/ml) (Boehringer Ingelheim, Germany) 5 µl  
 
Proteinase K                                                                                                                
20 mg/ml were dissolved in aqua bidest., aliquoted and stored at –20°C. 
 
 
Cutting buffer                                                                                                                                           
 
1 M Tris-HCl (pH 7.5, Roth, Germany)                                                             2.5 ml  
0.5 M EDTA (pH 8.0, Sigma, Germany)                                                                                     5.0 ml  
5 M NaCl (Roth, Germany)                                                                                  1.0 ml  
1 M DTT (Roth, Germany) 250 µl 
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Spermidine (500mg/ml, Sigma, Germany) 127 µl 
Aqua bidest ad 50 ml 
Storage at 4°C  
 
TE-buffer                                                                                                                                                 
 
10 mM Tris-HCl (pH 8.0, Roth, Germany)                                                                                         
1 mM EDTA  
Storage at 4°C.  
 
3.1.1.3 Polymerase chain reaction (PCR) 
One µl of the suspended DNA was mixed with 19µl of the Master Mix in PCR-
analysis cups (Kisker, Germany). DNA and components of the Mastermix were kept 
on ice during the procedure. The Taq DNA polymerase was stored at -20°C until it 
was added to the Mastermix. Taq DNA polymerase and Mastermix reagents were 
from the Taq PCR Master Mix Kit (Qiagen, Germany).  
Until further use, the PCR samples were stored at either 4°C (short-term) or at -20°C 
(long-term). DNA of a transgenic mouse was used as positive control, DNA of a wild-
type mouse was used as negative control and H2O served as quality (no template) 
control. The PCR was run in a Biometra® Uno II Thermocycler (Biometra, Germany), 
programmed as described: 
 
 
 
 
Mastermix  PCR-conditions  
      
Aqua bidest.              3.65 µl denaturation 94 °C   4 min  
Q-solution   4.00 ul denaturation 94 °C   1 min  
10 x buffer   2.00 µl annealing 60 °C   1 min 39 x 
MgCI2   1.25 µl extension 72 °C   2 min  
dNTP’s  (1mM)   4.00 µl final extension 72 °C 10 min  
sense primer        (Tra 1: 10 pM)      2.00 µl    
antisense primer  (Tra 3: 10 pM)     2.00 µl    
Taq Polymerase        0.10 µl    
template  1.00 µl    
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3.1.1.4 Gel electrophoresis 
DNA fragments were separated by size via electrophoresis in a TAE agarose (1.5%) 
gel (1.5 g agarose (Gibco BRL, Germany)/100 ml 1xTAE buffer), containing 9 µl/l 
ethidiumbromide (0.1%, Merck, Germany), casted in a Easy Cast® gel chamber 
(PeqLab, Germany) and filled with 1x TAE running buffer. The TAE running buffer 
also contained 9 µl/l ethidiumbromide (0.1%). Ethidiumbromide binds to double 
stranded DNA by interpolation between the base pairs and fluorescence may be 
seen when irradiated in the UV part of the spectrum. DNA samples were colored with 
4 µl of 6x loading dye (MBI Fermentas, Germany). At the beginning of each sample 
well row, 12 µl PUC Mix Marker #8 (MBI Fermentas, Germany) were placed in order 
to allow estimation of amplified fragment size. The remaining wells were filled with  
24 µl of the samples.  
Then electrophoresis was run for approximately 45 minutes at 90 V with an output of 
approximately 200 mA (Biorad Power PAC 300, Biorad, USA). Subsequently, the 
amplified products were visualized (Eagle Eye II, Stratagene, Germany) under UV 
light (306 nm) and a digital picture was taken to document the result. 
 
50x TAE stock solution 
Tris base (Roth, Germany) 
121 g  
glacial acetic acid (Sigma, Germany) 
28.55 ml  
EDTA, 0.5 M, pH 8.0 (Sigma, Germany)                                                                                      
50 ml  
ad 500 ml distilled water 
 
1x TAE-buffer                                                                                                               
10 ml 50x TAE-buffer ad 500 ml distilled water 
 
3.1.2 Uninephrectomy 
Initially, all mice were weighed to determine the correct dose of anesthesia. 
Urine was collected from each animal and 10 µl Meloxicam (Metacam®, 1.5 mg/ml, 
Boehringer, Germany) was administered orally. 
Mice were anesthetized by intraperitoneal injection of medetomidin (Domitor®,  
1 mg/ml, Pfizer AG, Germany), midazolam (Dormicum®, 5 mg/ml, Roche Pharma, 
Germany) and fentanyl (Fentanyl®- Janssen, 0.05 mg/ml, Janssen-Cilag, Germany).  
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After the anesthetic injection the mice were kept under an infrared heating lamp to 
stabilize the body temperature.  
As soon as surgical tolerance was reached, the mouse was placed on a warming-
pad. Eye ointment (Bepanthen®, Bayer, and Germany) was applied to both eyes and 
the coat was shaved from shoulder to hip on the left side. Following disinfection of 
the skin, an incision of approximately 1 cm was made vertically behind the costal 
arch. The left kidney was advanced, decapsulated and retained at the renal hilus by 
forceps. Below the forceps a ligature was made and the kidney was removed. The 
muscular layer was sutured with absorbable suture material (Vicryl, ETHICON, 
Germany). The skin was occluded with surgical clamps and wound powder 
(Sulfonamid-Kombi-Puder, Albrecht, Germany) was applied. 
The anesthesia was antagonized by intraperitoneal injection of atipamezol 
(Antisedan®, 5 mg/ml, Pfizer AG, Germany), flumazenil (Anexate®, 0.1 mg/ml, Roche 
Pharma, Germany) and naloxon (Narcanti®, 0.4 mg/ml, Bristol-Myers Squibb GmbH, 
Germany). The mice were placed under an infrared heating lamp until fully awake. 
In the following 5 days, each mouse was clinically examined and 10 µl Meloxicam 
(Metacam®, 1.5 mg/ml, Boehringer, Germany) was administered orally. 
10 days after the surgery, the surgical clamps were removed and normal hair growth 
was observed. 
 
3.2 Body weights 
Starting with the day of surgery at about 1 month, all animals were weight in intervals 
of 14 days. Last documentation of body weight was shortly before euthanasia. Body 
weight was determined to the nearest 0.1 g, using a precision scale (Kern KB 5000-1, 
Kern & Sohn GmbH, Germany).  
 
3.3. Blood pressure 
Blood pressure was non-invasively measured at 2 and 9 months of age by 
determining the tail blood volume with a volume pressure recording sensor and an 
occlusion tail-cuff (CODA System, Kent Scientific, USA).  
 
  
36
3.4 Blood glucose 
Blood glucose levels were measured in all mice at weaning. Blood was collected from 
the tail vein by drawing 10 l blood into a capillary. The blood samples were 
immediately put into an Eppendorf cup containing 500 l hemolysing solution (Roche, 
Germany). The blood glucose levels were determined using the Super GLeasy 
(Hitado, Germany). The system was calibrated with a control solution of known 
concentration and then the samples were measured. 
 
3.5 Serum parameters 
Blood was collected from the tail vein prior to euthanasia at 6 and 12 months and 
before 24 hour urine collection at 4 months of age. Serum was separated by 
centrifugation (10 min, 10,000 x g) and stored at -80°C until assayed.  
All serum samples were screened for chloride, total protein, creatinine, urea, 
triglyceride, glucose and albumin. Screening was performed with the Architect ci8200 
Autoanalyser (Abbott, Germany) and reagents supplied by Abbott. The testing was 
kindly done at the City Clinic Munich in Schwabing, Germany. 
 
3.6 Urine protein analysis 
Urine protein analysis was performed in order to evaluate clinical features of kidney 
damage. Urine samples were collected in monthly intervals between 1 and 6 months 
of age. Urine samples were always taken between two and three o’clock in the 
afternoon and immediately stored at -80 °C until assayed. In addition, the 24 hour 
urine was collected using metabolic cages (Techniplast, Germany) at the age of four 
months in all animals. 
 
3.6.1 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis 
(PAGE) 
At first, urine creatinine concentration was measured (kindly performed at the 
Medizinische Kleintierklinik, LMU Munich) using an automated analyzer technique 
(Hitachi, Merck, Germany). Urine samples were then diluted to a creatinine content of 
1.5 mg/dl, but at least 1:2 with reducing sample buffer. Subsequently, the diluted 
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samples were heated in a thermoblock TB1 (Biometra, Germany) for 10 minutes at 
100°C for denaturation of the proteins. In the meantime, a SDS-12% polyacrylamide 
gel was casted in a gel-casting chamber (Mini-Protean III, Biorad, Germany) and 
covered with isopropanol. After polymerization, the stacking gel was casted onto the 
SDS-12% gel; a comb for forming sample wells was immediately placed in the still 
fluid stacking gel. When the stacking gel was fully polymerized, the comb was 
removed and the gel was placed into an electrophoresis cell (Protean III, Biorad, 
Germany) which was then filled with running buffer to the top of the inside cell. The 
samples, a broad molecular weight standard (Biorad, Germany) and a mouse 
albumin standard (Biotrend, Germany) diluted 1:100 in sample buffer were then 
loaded onto the gel and electrophoresis was run for 60 minutes at 200 volt. The gel 
was removed from the glass frame and silver staining was performed due to a 
standard protocol (see 9.1). Clearly visible gel bands were registered and gels were 
photographed for documentation. Finally, gels were dried according to the 
manufacturer’s protocol (see 9.2), using the DryEase™Mini-Gel Drying System 
(Novex, Germany) for long-term storage. Materials used are listed below. 
 
Sample buffer 
 1 ml  Distilled water   
 0.25 ml Tris/HCl (Roth, Germany) 0.5 M pH 6.8   
 0.2 ml Glycerol (Merck, Germany)   
 0.4 ml SDS (Sigma, Germany) 10%    
 0.125 ml Bromphenol blue (Sigma, Germany) 0.05%  
 
Tris/HCl 0.5 M pH 6.8 
 6.075 g  Tris base (Roth, Germany)  
  ad 60 ml distilled water, adjust pH using 1N HCl (Merck, Germany) 
 
Running buffer (stock) 
 30.3 g Tris base (Roth, Germany)  
 144 g Glycine (Merck, Germany)  
  ad 1 l distilled water 
 
Running buffer (ready to use) 
 40 ml Stock solution  
  4 ml SDS (Sigma, Germany), 10%   
  ad 400 ml distilled water 
 
SDS-12% polyacrylamide gel 
 3.5 ml  Distilled water  
 2.5 ml  Tris/HCl (Roth, Germany) 1.5 M, pH 8.8  
 100 µl  SDS (Sigma, Germany) 10%  
 4.0 ml  Acrylamide (Roti Phenol, Germany)  
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 50 µl Ammonium persulfate 10% (Biorad, Germany) 
 5 µl  Tetraethylethylenediamine/ TEMED (Sigma, Germany)   
 
Stacking gel 
 6.1 ml  Distilled water 
 2.5 ml  Tris/HCl (Roth, Germay) 0.5 M, pH 6.8 
 100 µl  SDS (Sigma, Germany) 10% 
 1.3 ml  Acrylamide (Roti Phenol, Germany) 
 50 µl  Ammonium persulfate 10% (Biorad, Germany) 
 5 µl  Tetraethylethylenediamine/ TEMED (Sigma, Germany) 
 
 
3.6.2 Mouse albumin enzyme linked immuno-sorbent assay (ELISA) 
In addition to qualitative determination of proteinuria by SDS-PAGE, urinary albumin 
excretion was quantified by ELISA, using the mouse albumin ELISA-kit Bethyl E90-
134 (Bethyl, USA), according to the manufacturer’s protocol. All steps were 
performed at room temperature. Coating and blocking of plates was performed 
according to the manufacturer’s recommendations: 1 l (1 mg/ml) of goat anti-mouse 
albumin capture antibody (A90-134A) was diluted to 100 l coating buffer for each 
well to be coated. The coated plate (Nunc C bottom Immunoplate 96 well, Nunc A/S, 
Denmark) was incubated for 60 minutes. After incubation, the capture antibody 
solution was aspirated from each well. Each well was then filled with wash solution, 
which then was removed by aspiration. These washing steps were repeated for a 
total of 3 washes. 200 l of blocking (post-coat) solution were then added to each 
well and the plate was incubated for 30 minutes. After incubation, the blocking (post-
coat) solution was removed and each well was washed three times as described 
above. The murine albumin standard (calibrator) dilutions were prepared due to 
manufacturer’s recommendations (range: 7.8 - 500 ng/ml). Standards were diluted in 
sample diluent as described in table 2 below. The urine samples were diluted with 
sample diluent, based on the expected concentration of the analyses to fall within the 
concentration range of the standards. The proper dilution of urine specimens ranged 
from 1:50 - 1:1,600 (GIPRdn tg: 1:50 - 1:1,600, associated controls: 1:300 - 1:600), as 
shown by a pilot study. Standards, samples, blanks and controls were analyzed in 
duplicates. Each 100 l of standards or samples were transferred to the assigned 
wells. The plate was then incubated for 60 minutes. After incubation, samples and 
standards were removed and each well was washed 5 times as described above. 
The HRP conjugate (goat anti-mouse albumin-HRP conjugate, 1 mg/ml) was diluted 
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in conjugate diluent 1:100,000. 100 l of diluted HRP conjugate were transferred to 
each well and the plate was then incubated for 60 minutes. After incubation, the free 
HRP conjugate was removed and each well was washed 5 times. Subsequently, 
bound HRP antibody conjugate was detected through a chromogenic reaction. The 
substrate solution (TMB/H2O2, Kirkegaard and Perry, USA) was prepared by mixing 
equal volumes of the two substrate reagents, provided by the manufacturer. 100 l of 
substrate solution were added to each well and incubated for seven minutes. The 
TMB reaction was stopped by adding 100 l of 1 M H3PO4 (Roth, Germany) to each 
well. The color intensity was measured by determining the absorbance at 450 nm 
using a computer-assisted (Magellan, Tecan AG, Germany) microplate reader 
(Sunrise, Tecan AG, Germany). For calculation of results, the duplicate readings from 
each standard, control and sample were averaged. The zero reading was subtracted 
from each averaged value above. A standard curve was generated for each set of 
samples (Magellan, Tecan AG, Germany). The values of the specimen wells were in 
the linear segment of the calibration curve. For each group and stage of 
investigation, the albumin/creatinine ratios were calculated by dividing the measured 
albumin concentration of a urine sample by its corresponding creatinine 
concentration. Materials used for performance of ELISA-analyses are indicated 
below. 
 
Coating buffer 
0.05 M Carbonate-bicarbonate (Sigma, Germany) 
adjust to pH 9.6 
 
Wash solution 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
0.05% Tween 20 (Roth, Germany) 
adjust to pH 8.0 
 
Blocking (postcoat) solution 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
1% Bovine serum albumin in Tris buffered saline (Sigma Chemical, Germany) 
adjust to pH 8.0 
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Sample/conjugate diluent 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
1% Bovine serum albumin in Tris buffered saline (Sigma Chemical, Germany) 
0.05% Tween 20 (Roth, Germany) 
adjust to pH 8.0 
 
step ng/ml calibrator sample diluent 
0 10000 2 l 9 ml 
1 500 0.5 ml from step 0 9.5 ml 
2 250 1 ml from step 1 1 ml 
3 125 1 ml from step 2 1 ml 
4 62.5 1 ml from step 3 1 ml 
5 31.25 1 ml from step 4 1 ml 
6 15.625 1 ml from step 5 1 ml 
7 7.81 1 ml from step 6 1 ml 
 
Table 3: Preparation of murine albumin standard dilutions (range: 7.8 - 500 ng/ml) 
for quantification of urine albumin concentrations by ELISA (mouse albumin 
ELISA-kit Bethyl E90-134, Bethyl, USA) 
 
3.7. Glomerular filtration rate 
The glomerular filtration rate was calculated from serum creatinine, urine creatinine 
and 24 hour urine volume of samples collected in metabolic cages at 4 months of age 
as follows: 
creatinine(urine) * urine volume/ creatinine(serum) 
 
3.8 Kidney preparation and morphometric analysis 
At 1 month of age, the surgically removed left kidney was carefully separated from 
adjacent tissues, decapsulated, and weighed to the nearest mg, using a BP 61S 
scale (Satorius, Germany). The kidneys of 1-month-old animals were fixed by 
immersion in 4% neutral buffered formaldehyde solution, and processed for 
GMA/MMA- and Epon-embedding as described below.  
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3.8.1. Kidney perfusion 
Kidneys of uninephrectomized and sham operated transgenic and control animals 
were fixed via orthograde vascular perfusion at 6 an 12 months of age. All mice were 
weighed prior to sacrifice. Mice were euthanised by intraperitoneal injection of 300 µl 
of ketamine/xylazine solution, containing 1 ml Ketamine 10% (Selectavet, Germany), 
0.25 ml Xylazine 2% (Rompun 2%, Bayer, Germany), and 5 ml NaCl 0.9%. 
Perfusion was performed by initially opening the abdominal and thoracic cavity via 
incision. The left ventricle was penetrated with the perfusion needle and on starting of 
the perfusate flow, the inferior vena cava was cut cranial of the diaphragm to provide 
outflow of the perfusate. First, the vasculature was pre-flushed with 2 ml Lidocain 
(Lidocainhydrochlorid 2%, bela-pharm, Germany) in order to dilate the blood vessels, 
followed by perfusion with about 40 - 50 ml PBS (pH 7.4, 37°C) to wash the blood out 
of the circulation. A slice of approximately 1 mm thickness was carefully cut from one 
pole of the right kidney, using a scalpel blade and frozen in liquid nitrogen. Then, 
perfusion with warm (37°C) 3% glutaraldehyde (6 month of age) or 4% 
paraformaldehyde (12 months of age) in PBS (pH 7.4) was performed for 5 minutes.  
After postfixation for 24 hours in the same fixans used for perfusion, kidneys were 
removed carefully, separated from adjacent tissues, weighed to the nearest mg, cut 
perpendicular to the longitudinal axis into slices of approximately 2 mm thickness and 
samples for Epon embedding were taken by systematic random sampling (see 
below). In order to avoid distortions, the kidney slices were fixed with a piece of foam-
rubber sponge (Bio Optica, Italy) in the tissue-embedding capsules (Engelbrecht, 
Germany). Embedding in glycolmethacrylate and methylmethacrylate (GMA/MMA) 
was performed (Hermanns et al., 1981). Kidney slices were immersed in a 
hydroxymethylmethacrylate (Fluka Chemie, Germany) / methylmethacrylate (Riedel 
de Haën, Germany) solution at 4°C on a shaker for 18 hours. The kidney slices were 
then shifted into “solution A”, composed of benzoylperoxide (338 mg; Merck, 
Germany), methylmethacrylate (20 ml), hydroxymethylmethacrylate (60 ml), 
ethyleneglycol monobutylether (16 ml; Merck, Germany) and polyethylene glycol 400 
(2 ml; Merck, Germany). After immersion at 4°C on a shaker for four hours, the 
kidney slices were placed in plastic cups and embedded using 60 µl of dimethylanilin 
(Merck, Germany) in 40 ml of “solution 1” as starter for polymerisation. Embedding 
cups were immediately placed into a water bath (4°C) and polymerisation took place 
at 4°C over night. Sections of approximately 1.5 µm thickness were cut using a 
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Microm HM 360 rotary microtome (Microm, Germany), dried on a heating plate (OTS 
40, Meditel, Germany) and stored in an incubator (Memmert, Germany) at 64°C over 
night before staining. Sections were stained with PAS (Periodic Acid Schiff stain), 
PASM (periodic acid silver methenamine) PAS, and H&E (Hematoxilin & Eosin), as 
indicated below.  
 
3.8.2. Processing for plastic histology 
 
Phosphate-buffered saline (PBS) 
potassium dihydrogen phosphate (AppliChem, Germany) 0.25 g 
sodium chloride (AppliChem, Germany) 8.0 g 
di-sodium hydrogen phosphate dihydrate (AppliChem,Germany) 1.46 g 
ad 1 l distilled water, adjust to pH 7.4 
 
Dehydration 
Rinsing solution       3 hours 
Ethyl alcohol 30 %        2 x 1 hour 
(Bundesmonopolverwaltung für Branntwein, Germany)  
Ethyl alcohol 56 %       2 x 1 hour 
Ethyl alcohol 70 %       2 x 1 hour 
Ethyl alcohol 96 %       2 hours 
Ethyl alcohol 96 %       2 x 3 hours 
 
Periodic acid-Schiff stain (PAS) 
1. 1% periodic acid (Applichem, Germany)  15 minutes 
2. Distilled water      3 times 3 seconds 
3. Schiff‘s reagent (Merck, Germany)   30-60 minutes 
4. Rinse in tap water     30 minutes 
Dry 
Mayer‘s hemalaun (Applichem, Germany)  35 minutes 
Rinse in tap water      10 minutes 
1% HCl alcohol      1 second 
Rinse in tap water      10 minutes 
Dry 
Mount under glass cover slips using Histofluid® (Superior, Germany) 
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H&E staining 
1. Mayer‘s hemalaun (Applichem, Germany)  30 minutes 
2. Rinse in tap water     10 minutes 
3. 1% HCl-Alcohol      1 second 
4. Rinse in tap water     10 minutes 
6. Dry 
7. Eosine Y (Merck, Germany)    5 minutes 
8. Distilled water      3 times 3 seconds 
9. Dry 
10. Mount with glass cover slips using Histofluid® (Superior, Germany) 
 
PASM PAS stain (Gomori 1946) modified 
1.  1% periodic acid (Applichem, Germany) 15 minutes 
2.  Distilled water     3 times 3 seconds 
Dry 
Silver-methenamine solution containing:  
 3% Methenamine solution    50 ml 
5% Silver nitrate (Applichem, Germany)  2.5 ml 
2% Sodium tetraborate decahydrate (Borax) 6 ml 
Distilled water     45 ml 
Pre-heat to 60° in a water bath    5 minutes 
Staining (shake in a closed water bath at 60°C) 15-50 minutes, staining  
intensity has to be controlled  
repeatedly  
Distilled water      3 times 3 seconds 
1.5% Sodium thiosulphate solution    2 minutes 
Rinse in tap water      5 minutes 
Dry 
Schiff‘s reagent (Merck, Germany)   60 minutes 
Rinse in tap water      30 minutes 
Dry 
Mayer‘s hemalaun (Applichem, Germany)  25 minutes 
Rinse in tap water      10 minutes 
1% HCl alcohol      1 second 
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Rinse in tap water      10 minutes 
Dry 
Mount under glass cover slips using Histofluid® (Superior, Germany) 
 
3.8.3. Tissue preparation for Epon embedding 
For the preparation of semithin sections for quantitative stereological analyses in 1- 
and 6-month-old animals, three cubes (1mm3) of cortical kidney tissue from each 
animal and kidney were taken by systematic random sampling, postfixed in 1% 
osmiumtetroxide (OsO4, Merck, Germany), dehydrated and embedded in Epon (syn. 
“glycid ether 100”, Serva, Germany) according to standard procedures: The samples 
were washed for 3 hours in Sörensen phosphate buffer at room temperature, 
postfixed in 1% osmium tetroxide (Caulfield 1957) for 2 hours at 4°C, and washed in 
Sörensen phosphate buffer three times for 2 min at room temperature. Subsequently, 
the specimens were dehydrated through a series of acetone (Roth, Germany) 
solutions at 4°C. Then they were infiltrated with a 100% acetone/Epon mixture for 1 
hour, and twice with pure Epon for 30 min each, at room temperature. Then, the 
Epon infiltrated samples were embedded in Epon-embedding mixture in dried gelatin 
capsules (Plano, Germany). Polymerization took place at 60°C for approximately 48 
hours. Epon blocks were trimmed with a TM60 Reichert-Jung milling machine (Leica, 
Germany) and 0.5 µm semi-thin sections were obtained with a Reichert-Jung 
"Ultracut E" (Leica, Germany). Sections were then stained with Azur II/Safranin, as 
indicated below.  
 
The following materials were used for Epon histology: 
 
 
80.8 ml 
  19.2 ml 
Sörensen phosphate buffer 0.067 M, pH 7.4 
Solution I 
Solution II 
adjust to pH 7.4 
9.08 g
 
Solution I 
potassium dihydrogen phosphate (Roth, Germany)  
ad 1 l distilled water 
 
Solution II 
di-sodium hydrogen phosphate dihydrate (Roth, Germany) 
ad 1 l distilled water 
11.88 g
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2.95 g
Veronal acetate buffer, pH 7.6 
sodium veronal  (barbitone sodium, Merck, Germany) 
sodium acetate (Merck, Germany)                                                      1.94 g
5.0 ml
2.0 ml 
ad 100 ml distilled water 
 
Osmium tetroxide, 1% 
osmium tetroxide, 2% (Merck, Germany) 
veronal acetate buffer, pH 7.6 
hydrogen chloride 0.1 M (Merck, Germany) 2.0 ml
1.0 ml distilled water 
Saccharose (Merck, Germany) 0.45 g
62 ml
 
Solution A 
glycid ether 100 (Serva, Germany) 
2-dodecenyl succinicacid anhydride (Serva, Germany) 
   100 ml
 
100 ml
 
Solution B 
glycid ether 100 (Serva, Germany) 
methylnadic anhydride (Serva, Germany) 89 ml
 
Epon-embedding mixture 
solution A                                                                                                                3.5 ml 
 
solution B                                                                                                               6.5 ml 
para-dimethyl aminomethyl phenol (Serva, Germany)                                         0.15 ml
 
 
Azur II/Safranin staining protocol for semithin sections 
 
1.0 g 
100 ml
1.0 g
Azur II solution                                                                                                                                                   
Disodium tetraborate (Merck 6306, Germany) 
Aqua dest.  
Azur II (Merck 9211, Germany) 
37% Formaldehyde (Roth, Germany) 
250 µl
Dissolve borate in aqua dest., then add Azur II and stir for approximately two hours 
before adding formaldehyde. Filter prior to use. 
 
Safranin O solution 
 
1.0 g 
100 ml
Disodium tetraborate (Merck 6306, Germany) 
Aqua dest.  
Safranin O (Chroma 1B 463, Germany) 1.0 g
40.0 gSaccharose  (Merck, Germany) 
37% Formaldehyde (Roth, Germany) 250 µl
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Dissolve borate in aqua dest., then add Safranin and saccharose. Stir for 
approximately two hours before adding formaldehyde. Filter prior to use. Stain 
sections in Azur II solution for 15-20 seconds at 55°C on a heating plate (Meditel, 
Germany) and rinse with distilled water. Dry. Then stain sections for 15-20 seconds 
at 55°C on a heating plate (Meditel, Germany) and rinse with distilled water. Dry. 
Cover sections with glass coverslips (Menzel GmbH & Co KG, Germany) using 
Histofluid® (Superior, Germany). 
 
3.8.4. Quantitative stereological analyses 
3.8.4.1 Estimation of the mean glomerular volume 
The kidney volume was calculated dividing the kidney weight by the specific weight of 
mouse kidneys (1.05 mg/mm3) (Wanke 1996). The mean glomerular volume was 
estimated, using a model-based method, as previously described in detail(Hirose et 
al., 1982, Wanke 1996, Weibel and Gomez 1962). In this model-based stereological 
approach, the glomeruli were considered as rotation ellipsoids. The mean glomerular 
area was obtained from planimetric measurements of glomerular profile areas. In the 
calculation, a shape coefficient and a size distribution coefficient were considered. 
The results were corrected for embedding shrinkage. The values for the shape and 
size distribution coefficient as well as for the shrinkage correction factor for plastic 
embedded murine renal tissue were taken from Wanke (1996). Morphometric 
evaluation was carried out on a Videoplan® image analysis system (Zeiss-Kontron, 
Germany) coupled to a light microscope (Orhoplan; Leitz, Germany) via a color video 
camera (CCTV WV-CD132E; Matsushita, Japan). Images of PAS stained 
GMA/MMA-embedded sections were displayed on a color monitor at a 400x final 
magnification. The profiles of about 100 glomeruli per animal (mean 105 ± 5) were 
measured planimetrically by circling their contours with a cursor on the digitizing 
tablet of the image analysis system after calibration with an object micrometer (Zeiss, 
Germany).  
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The stereologically estimated mean glomerular volume was calculated as the product 
of the mean glomerular area to the power of 1.5 and the shape coefficient (ß=1.40), 
divided by the size distribution coefficient (k=1.04) (Weibel 1980). Results were 
corrected for embedding shrinkage, using the linear tissue shrinkage correction factor 
(fs = 0.91) for murine kidney tissue embedded in GMA/MMA (Wanke 1996): 
v Glom A
k
∗=
β
Glom
1.5
  
/fs3 
 
3.8.4.2. Estimation of the mean glomerular mesangium and capillary volumes 
The mesangial and capillary volume fractions (Vv(Mes/Glom) and Vv(Cap/Glom), 
respectively) were determined on PAS-stained plastic sections by point counting, 
using a computer-assisted stereology system (NewCast, Visiopharm, Denmark) at 
the age of 1 and 6 months. The sum of all points hitting mesangium or capillaries was 
divided by the sum of points hitting glomeruli. On the average 40 whole glomeruli 
(range 30-46) were evaluated (corresponding to 265-670 reference points). The 
mean glomerular mesangium or capillary volumes (v(Mes,Glom) and vCap,Glom), 
respectively) were obtained by multiplying the respective volume fraction by v (Glom).  
 
3.8.4.3. Estimation of total numbers and mean volumes of podocytes 
The number of podocytes per glomerulus was estimated by applying the physical 
disector principle at the age of 1 and 6 months. The disector is a three dimensional 
stereologic probe, which allows unbiased and assumption free counting and sizing of 
particles (Sterio 1984). The physical disector, which consists of a pair of physical 
section planes separated by a known distance, was used to estimate the numerical 
density of podocytes. In each case eight serial semithin sections (nominal thickness 
0.5 µm) of the Epon-embedded samples of cortical kidney tissue were cut with an 
Ultracut E microtome (Leica, Germany), mounted on glass slides and stained with 
Azur II/Safranin. Photographs of complete profiles of identical glomeruli, present in 
the centre of two semithin sections (reference section and look-up section; disector 
height: 1.5 µm), were taken at a magnification of x 400 using a Leica DFC 320 
camera (Leica, Germany) connected to a microscope (Orthoplan, Leitz, Germany). At 
the beginning of each set, an object micrometer (Zeiss, Germany) was photographed 
under the same conditions for calibration. Prints of all pictures were made at a 
constant setting of the enlarger. Prints of pictures of nine pairs of glomerular profiles 
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from each animal were analyzed. The areas of the glomerular profiles were 
measured planimetrically on these prints by circling their contours with a cursor on 
the digitizing tablet of the image analysis system (Zeiss-Kontron, Germany) after 
calibration. All nuclei of podocytes (P) sampled in the reference section, which were 
not present in the look-up section, were counted (Q-(P)). The process of counting was 
then repeated by interchanging the roles of the reference and look-up section, 
thereby increasing the efficiency by a factor of two.  
The numerical density of podocytes in glomeruli was calculated as 
3
)(
)(
)/( fsAh
Q
N
Glom
P
GlomPV ×
×
= ∑
∑ −
 where h was the disector height (1.5 µm) and fs the 
linear tissue shrinkage correction factor for Epon embedded murine kidney tissue 
(0.95) (Wanke 1996). 
The number of podocytes per glomerulus ( ),( GlomPN ) was calculated multiplying 
)/( GlomPVN and v (Glom).  
The volume fraction of podocytes per glomerulus (Vv(P/Glom)) was determined by point 
counting method. The mean podocyte volume ( )(Pv ) was calculated dividing Vv(P/Glom) 
by )/( GlomPVN . 
 
3.9 Data presentation and statistical analysis 
Data is presented as means ± SEM or SD as indicated. Statistical significance of 
differences between two groups was calculated by one-way ANOVA and LSD test, 
using GraphPad Prism 5.0 (GraphPad Software, Inc, USA). P values < 0.05 were 
considered significant. The albumin-to-creatinine ratios (ACR) were logarythmized to 
normalize their distribution (van Goor et al., 1991). 
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4. Results 
4.1 Body weight 
Body weights were determined from 1 month of age onwards in 2-week intervals. 
From about 2 to 6 months of age, the body weight of transgenic animals was 
significantly lower than that of control mice. Uninephrectomy had no influence on 
body weights of transgenic or control mice vs. the respective sham operated 
counterparts (Fig. 4.1) 
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Fig. 4.1.: Body weights of uninephrectomized (unx) and sham operated (sham) 
transgenic (tg) and wild-type (wt) mice. 
Data are means and SEM; n ≥ 5/group; * p<0.05 wt sham vs. tg sham; $ p<0.05 wt unx vs. tg unx.  
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4.2 Blood pressure 
 
Systolic and diastolic blood pressure did not differ between the groups irrespective of 
the age at sampling (Fig. 4.2.). 
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Fig. 4.2.: Systolic (A) and diastolic (B) blood pressure of uninephrectomized (unx) 
and sham operated (sham) transgenic (tg) and wild-type (wt) mice at 2 and 9 months 
of age. 
Data are means and SEM, n ≥ 4/group  
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4.3 Blood and serum glucose 
Blood glucose levels of 21-day-old transgenic mice were significantly higher than 
those of control mice. There was no difference in blood glucose levels between 
animals that were to be sham operated or uninephrectomized in either the wild-type 
or the transgenic group (Fig. 4.3).  
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Fig. 4.3: Blood glucose levels at 21 days of age of transgenic (tg) and wild-type (wt) 
mice that were selected for either future uninephrectomy (unx) or sham operation 
(sham). Data are means and SEM, different superscripts indicate significant differences between 
groups. n ≥ 5/group. 
 
Serum glucose levels of transgenic mice were significantly higher than those of wild-
type mice; Uninephrectomy had no influence on serum glucose concentrations of 
either transgenic or control mice (Table 4.1). 
 
  
52
 
group   /    age 4 months 6 months 12 months 
wt sham 167 ± 25 164 ± 33 135 ± 38 
wt unx 165 ± 30 151 ± 15 108 ± 37 
tg sham 804 ± 89* 819 ± 68* 790 ± 147* 
tg unx 809 ± 162$ 850 ± 201$ 778 ± 191$ 
 
Table 4.1 Serum glucose concentrations (mg/dl) of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 4, 6 and 12 
months of age. Data are means and SD; n=6 animals/group; * p<0.05 wt sham vs. tg sham; $ 
p<0.05 wt unx vs. tg unx.  
 
4.4 Serum parameters 
The serum samples of all animals at four, six, and twelve months of age were 
screened for chloride, total protein, creatinine, urea, triglyceride, and albumin. 
Serum urea, creatinine and triglycerides of sham operated and uninephrectomized 
transgenic animals were slightly or significantly increased and total protein, albumin 
and chloride levels were slightly or significantly decreased vs. the respective controls, 
irrespective of the age at sampling. Uninephrectomized wild-type and transgenic 
mice exhibited slightly higher urea levels vs. the respective sham operated mice.  
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Group Urea (mg/dl) 
Creatinine 
  (mg/dl) 
TG 
(mg/dl) 
Total 
protein 
(g/l) 
Albumin 
(g/l) 
Chloride 
(mmol/l) 
4 months 
wt sham 58 ± 12 0.4 ± 0.0& 101 ± 61& 5.8 ± 0.2* 3.4 ± 0.2 111 ± 4 
wt unx 80 ± 17 0.5 ± 0.1§ 108 ± 79& 5.7 ± 0.2* 3.3 ± 0.2 109 ± 5 
tg sham 89 ± 39 0.6 ± 0. 1* 149 ± 70& 5.2 ± 0.3* 3.0 ± 0.2* 106 ± 6* 
tg unx 99 ± 44 0.7 ± 0.1$  188 ± 104$ 5.0 ± 0.4$ 2.8 ± 0.4$ 107 ± 6 
6 months 
wt sham 167 ± 19 0.4 ± 0.0 185 ± 21 5.3 ± 0.3 3.2 ± 0.2 111 ± 2 
wt unx 188 ± 18 0.4 ± 0.0 129 ± 42 5.1 ± 0.5 3.2 ± 0.2 109 ± 4 
tg sham 185 ± 24 0.6 ± 0.1* 184 ± 113* 4.9 ± 0.4 2.8 ± 0.2* 104 ± 4* 
tg unx 103 ± 26 0.5 ± 0.1$% 196 ± 55 4.6 ± 0.3$ 2.7 ± 0.2$ 100 + 0$ 
12 months 
wt sham 61 ± 12 0.4 ± 0.0 105 ± 33 5.8 ± 0.2 3.5 ± 0.2 108 ± 1 
wt unx 66 ± 33 0.4 ± 0.1 224 ± 273 5.4 ± 1.8 3.0 ± 1.0 195 ± 25 
tg sham 65 ± 8 0.6 ± 0.2* 211 ± 48* 5.4 ± 0.2* 3.0 ± 0.2* 108 ± 5 
tg unx 82 ± 31 0.8 ± 0.1$% 180 ± 30 5.3 ± 0.1 3.0 ± 0.0 107 ± 1 
 
Table 4.2 Serum parameters of sham operated (sham) and uninephrectomized (unx) 
transgenic (tg) and wild-type (wt) mice at 4, 6 and 12 months of age. Data are means 
and SD; n= 6 animals/group; TG, triglycerides; * p<0.05 wt sham vs. tg sham; $ p<0.05 wt unx vs. tg 
unx § p<0.05 wt vs. wt; % p<0.05 tg vs. tg. 
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4.5 Urine analyses 
GIPRdn transgenic mice exhibited selective glomerular proteinuria at 4 and 5 months 
of age compared to their corresponding non transgenic littermate controls. Bands of 
approximately 69 kDa, which meets the size of murine albumin, were detected by 
SDS-PAGE. Excretion of proteins larger than 37 kDa was not detectable in the urine 
samples of controls. Bands in the region of approximately 18 kDa reflect major 
urinary proteins (MUPs), which appear in the murine urine under physiological 
conditions particularly in male mice.  
 
      (A) SDS-PAGE gel 1                                 (B) SDS-PAGE gel 2 
      
    Alb   1      2    4      5     6     7     8    M      Alb   1    2     3    4     5    6    7     8    M 
 
Fig. 4.4.: (A/B) SDS-PAGE of urine samples of uninephrectomized GIPRdn transgenic 
(# 1-3), sham operated transgenic (# 4-6), sham operated control (# 7), and 
uninephrectomized control (# 8) mice at (A) 4 and (B) 5 months of age.  
Alb: Mouse albumin standard, M: Precision Protein Standard (BIORAD, Germany), molecular weight 
from top to bottom: 250, 150, 100, 75, 50, 37, 18 kDa.  
 
 
Urinary albumin and creatinine concentrations were determined from 1 until 6 months 
of age in about monthly intervals and the albumin-to-creatinine ratio (ACR) was 
calculated. Urinary creatinine levels of transgenic mice were significantly lower than 
those of wild-type mice from about one and a half months of age onwards (Fig. 4.5).  
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Fig. 4.5. Urinary creatinine concentrations of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice between 1 and 6 
months of age. Data are means and SEM; n ≥ 4/group; * p<0.05 wt sham vs. tg sham; $ p<0.05 wt 
unx vs. tg unx  
 
From about 2 months of age, both uninephrectomized and sham operated transgenic 
mice exhibited a higher ACR as compared to the respective control mice. The ACR of 
sham operated transgenic mice was increased up to 3-fold, that of 
uninephrectomized transgenic mice was increased up to 92-fold vs. the respective 
wild-type mice. In addition, uninephrectomized transgenic mice showed a significantly 
higher ACR vs. sham operated GIPRdn transgenic mice. Uninephrectomy had no 
influence on the ACR of wild-type mice (Fig. 4.6). 
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Fig. 4.6. Urinary albumin-to-creatinine ratio (ACR) of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice between 1 and 6 
months of age. Time of operation was at 1 month. Data are means and SEM; n ≥ 4/group; * p<0.05 
wt sham vs. tg sham; $ p<0.05 wt unx vs. tg unx; % p<0.05 tg vs. tg 
 
At 4 months of age, 24 hour urine was collected and the ACR in 24 hour urine 
samples was calculated. The urine volume of transgenic animals was significantly 
higher that that of the respective control mice, irrespective of the kind of operation 
(Fig. 4.7). Uninephrectomized and sham operated transgenic mice exhibited 
significantly higher ACR in 24 hour urine samples than the corresponding control 
mice. The ACR in 24 hour urine samples of sham operated transgenic mice was 
increased 700-fold, that of uninephrectomized transgenic mice was increased 400-
fold vs. the respective wild-type controls. Uninephrectomized transgenic mice 
showed a significantly higher ACR in 24 hour urine samples than sham operated 
transgenic animals (Fig. 4.8.). 
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Fig. 4.7. Daily urine volume of sham operated (sham) and uninephrectomized (unx) 
transgenic (tg) and wild-type (wt) mice at 4 months of age. Data are means and SEM; n ≥ 
6/group; Different superscripts indicate significant differences between groups (p<0.05) 
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Fig. 4.8 Albumin-to-creatinine ratio (ACR) in 24 hour urine samples of sham operated 
(sham) and uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 4 
months of age; Data represent means and SEM; n ≥ 6/group; Different superscripts indicate 
significant differences between groups (p<0.05)  
 
4.6 Glomerular filtration rate 
 
The glomerular filtration rate (GFR) was calculated from urine creatinine, urine 
volume and serum creatinine at 4 months of age. Both uninephrectomized and sham 
operated GIPRdn transgenic mice showed a significantly reduced GFR vs. the 
respective control mice. The GFR of uninephrectomized transgenic mice was 
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significantly lower than that of sham operated transgenic mice. In wild-type mice, 
uninephrectomy did not influence the GFR (Fig 4.9). 
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Fig. 4.9. Glomerular filtration rate (GFR) of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 4 months of age; 
Data represent means and SEM; Different superscripts indicate significant differences between groups 
(p<0.05)  
 
4.7 Qualitative histological findings of the kidneys 
 
The uninephrectomized left kidneys of 1-month-old transgenic mice did not show 
macroscopical or histological abnormalities vs. wild-type mice. The kidneys of 6- and 
some 12-month-old transgenic mice appeared enlarged and the renal pelvis was 
sometimes slightly dilated vs. wild-type mice. In addition, the ureters and bladders of 
transgenic animals were frequently dilated as compared to wild-type mice. There 
were no differences in these macroscopical aspects comparing uninephrectomized 
and sham operated transgenic mice. One uninephrectomized GIPRdn transgenic 
mouse aged about 7 months showed renal atrophy with a granular kidney surface 
(Fig. 4.10). The kidneys of uninephrectomized wild-type mice appeared larger than 
those of sham operated control mice.  
Histologically, glomeruli of 6- and 12-month-old GIPRdn transgenic mice appeared 
enlarged, showed focal to diffuse segmental to panglomerular mesangial expansion, 
focal glomerulosclerosis, synechia between the glomerulus, and the capsule of 
Bowman and large distorted capillaries. Tubulo-interstitial lesions of transgenic mice 
included protein reabsorption droplets in proximal tubular epithelia, proteinaceous 
casts in distal tubules, focal tubular atrophy and few focal interstitial mononuclear 
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inflammatory cell infiltrates. The mentioned glomerular and tubulo-interstitial changes 
were more severe in some 12-month-old uninephrectomized transgenic mice vs. 6-
month-old transgenic mice. The single uninephrectomized GIPRdn transgenic mouse 
exhibiting the atrophic kidney mentioned above showed diffuse panglomerular 
glomerulosclerosis and glomerular hyalinosis with numerous obsolescent glomeruli, 
and focal cystic dilation of the capsule of Bowman. In addition, multiple tubular cysts, 
severe interstitial fibrosis with mononuclear infiltrates, pigment laden macrophages 
and signs of proteinuria were evident. Both sham operated and uninephrectomized 
wild-type mice developed focal segmental mesangium expansion and few foci of 
interstitial fibrosis with lymphoplasmacellular infiltrates, these changes being more 
severe in 12- than in 6-month old wild-type mice and more pronounced in 
uninephrectomized vs. sham operated wild-type mice. Some glomeruli of 12-month-
old uninephrectomized wild-types showed large distorted capillaries. Proteinaceous 
casts and tubular atrophy were rarely observed in wild-type mice (Figures 4.11 A-P). 
 
 
Fig. 4.10 Perfusion fixed kidney of an about 7-month-old uninephrectomized GIPRdn 
transgenic mouse that is unusually small (300 mg vs. about 600 to 1000 mg in other 
uninephrectomized transgenic mice) and exhibits a granular surface.  
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Fig. 4.11 Histology of the kidneys of sham operated (sham) and uninephrectomized 
(unx) transgenic (tg) and wild-type (wt) mice at 6 (A-F, M-P), 12 (G-J) and 7 months 
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of age (K,L). A) wt sham showing normal renal architecture; B) tg sham showing 
mesangial expansion and tubular atrophy (top right); C) wt unx showing glomerular 
hypertrophy; D-F) tg unx, showing mesangium expansion and synechia between the 
glomerular tuft and the capsule of Bowman (in D,E), tubular atrophy and signs of 
proteinuria (in F); G) wt sham showing a tubular cyst; H) tg sham, showing mesangial 
expansion signs of proteinuria, and a small focus of interstitial fibrosis; I) wt unx 
showing focal interstitial fibrosis and mononuclear cell infiltration; J-L) tg unx showing 
panglomerular mesangial expansion, focal fibrosis (in J), glomerulosclerosis with 
sometimes glomerular obsolescence, dilated tubules with proteinaceous casts, 
interstitial fibrosis, mononuclear infiltration and pigment laden cells (in K,L); M-P 
glomerular profiles of M) wt, unx without pathological changes; N) tg sham 
demonstrating mesangial expansion and matrix accumulation; O) tg unx  showing 
segmental glomerulosclerosis with synechia formation; P) tg unx exhibiting 
glomerular obsolescence due to hyalinosis; Bar in  A-L 100 µm, in M-P 50 µm; A-F, 
M-P) PASM-PAS stained plastic sections; G-L) H&E-stained plastic sections  
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4.8. Quantitative stereological findings of the kidneys 
4.8.1 Kidney volume  
 
The kidney volumes of the uninephrectomized left kidneys (age 1 month) and of the 
kidney remnant or the right kidneys of sham operated animals (age 6 and 12 months) 
was determined. At time of uninephrectomy, there were no differences in kidney 
weights of transgenic and control mice. At 6 months of age, the kidney volumes of 
uninephrectomized and sham operated transgenic mice were significantly higher than 
those of their respective controls. Uninephrectomy led to a significantly increased 
kidney volume vs. sham operation in both 6-month-old GIPRdn transgenic and wild-
type mice. The kidney volumes of 12-month-old uninephrectomized wild-type mice 
were significantly higher than those of age-matched sham operated controls. There 
were no differences in the kidney volumes of transgenic mice vs. controls or between 
the two transgenic groups at 12 months of age. (Fig. 4.12) 
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Fig. 4.12. Kidney volumes of sham operated (sham) and uninephrectomized (unx) 
transgenic (tg) and wild-type (wt) mice at 1, 6 and 12 months of age; Data represent 
means and SEM; Different superscripts indicate significant differences between groups (p<0.05). Data 
at 1 month of age represent kidney volumes of the removed left uninephrectomized kidney, data of 
uninephrectomized animals at 6 months of age are kidney volumes of the right kidneys of the same 
animals. 
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4.8.2 Mean glomerular volume  
 
The mean glomerular volume of the uninephrectomized left kidneys (age 1 month) 
and of the kidney remnant or the right kidneys of sham operated animals (age 6 and 
12 months) was determined, using quantitative stereological techniques.  
At time of uninephrectomy, there were no differences in the mean glomerular 
volumes, comparing transgenic and control mice. At 6 months of age, the mean 
glomerular volumes of uninephrectomized and sham operated transgenic mice were 
significantly higher than those of their respective controls. Uninephrectomy led to a 
significantly higher mean glomerular volume vs. sham operation in both GIPRdn 
transgenic and wild-type mice, and uninephrectomized wild-type mice exhibited an 
equal mean glomerular volume as sham operated transgenic mice. At 12 months of 
age, sham operated transgenic animals exhibited a higher mean glomerular volume 
vs. sham operated wild-type mice and uninephrectomized wild-type mice displayed a 
significantly higher mean glomerular volume as compared to sham operated wild-
type mice. Uninephrectomized and sham operated 12-month-old transgenic and 
uninephrectomized wild-type showed equal mean glomerular volumes. The mean 
glomerular volume
 
increased significantly in both uninephrectomized wild-type and 
transgenic animals from 1 to 6 months of age. Sham operated 12-month-old 
transgenic animals exhibited a significantly higher mean glomerular volume vs. their 
6-month-old counterparts, in all other groups the mean glomerular volume did not 
change between 6 and 12 months of age. Interestingly, uninephrectomy of wild-type 
mice led to a similar degree of glomerular hypertrophy as hyperglycemia in sham 
operated GIPRdn transgenic mice (Fig. 4.13). 
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Fig 4.13. Mean glomerular volume of sham operated (sham) and uninephrectomized 
(unx) transgenic (tg) and wild-type (wt) mice at 1, 6 and 12 months of age; Data 
represent means and SEM; Different superscripts indicate significant differences between groups 
(p<0.05). Data at 1 month of age represent mean glomerular volumes of the removed left kidney, data 
of uninephrectomized animals at 6 months of age are mean glomerular volumes of the right kidneys of 
the same animals. 
 
4.8.3 Volume densities of capillaries and mesangium per glomerulus and mean 
glomerular mesangium and capillary volumes  
 
The volume densities of mesangium and capillaries per glomerulus were not different 
between groups (Table 4.3).  
 
Table 4.3 Volume densities of 
mesangium (Vv(Mes/glom) and 
capillaries (Vv(Cap/Glom) per 
glomerulus of sham operated 
(sham) and uninephrectomized 
(unx) transgenic (tg) and wild-type 
(wt) mice at 1 and 6 months of age. 
(n), number of animals investigated; data 
are means and SD;   
 
 
 
Group Vv(Mes/Glom) (%) 
Vv(Cap/Glom) 
(%) 
1 month 
wt unx (6) 41 ± 6 32 ± 5 
tg unx (6) 42 ± 5 35 ± 5 
6 months 
wt unx (6) 40 ± 7 33 ± 4 
tg unx (6) 37 ± 7 38 ± 5 
wt sham (6) 38 ± 6 37 ± 7 
tg sham (6) 37 ± 6 36 ± 5 
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The mean glomerular mesangium volume (v(Mes,Glom)) of 6-month-old transgenic mice 
was significantly higher than that of the respective controls. Uninephrectomy led to a 
significant increase of the v(Mes,Glom) of both transgenic and wild-type mice vs. the 
respective sham operated control animals. There was no difference between 
v(Mes,Glom) of uninephrectomized wild-type and sham operated transgenic animals, 
therefore uninephrectomy in healthy animals leads to the same extent of mesangial 
expansion as hyperglycemia. The v(Mes,Glom) increased significantly in both 
uninephrectomized wild-type and transgenic animals from 1 to 6 months of age (Fig. 
4.14) 
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Fig 4.14. Mean glomerular mesangium volume of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 1 and 6 months of 
age; Data represent means and SEM; Different superscripts indicate significant differences between 
groups (p<0.05) Data at 1 month of age represent mesangial volumes of the removed left kidney, data 
of uninephrectomized animals at 6 months of age are mesangial volumes of the right kidneys of the 
same animals. 
 
The mean glomerular capillary volume (v(Cap,Glom)) of 6-month-old transgenic mice 
was significantly higher than that of the corresponding controls. Uninephrectomy led 
to a significant increase of the v(Cap,Glom) of transgenic mice vs. sham operated 
transgenic animals. There was no difference in v(Cap,Glom) between uninephrectomized 
wild-type and sham operated wild-type or sham operated transgenic animals. The 
v(Cap,Glom) increased significantly in both uninephrectomized wild-type and transgenic 
animals from 1 to 6 months of age (Fig. 4.15) 
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Fig 4.15. Mean glomerular capillary volume of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 1 and 6 months of 
age; Data represent means and SEM; Different superscripts indicate significant differences between 
groups (p<0.05). Data at 1 month of age represent capillary volumes of the removed left kidney, data 
of uninephrectomized animals at 6 months of age are capillary volumes of the right kidneys of the 
same animals. 
4.8.4 Numerical volume density of podocytes in glomeruli 
 
The numerical volume density of podocytes in glomeruli (Nv(Podo/Glom)) of 6-month-old 
transgenic mice was significantly lower than that of the respective wild-type mice. 
Uninephrectomy in wild-type mice led to a slight decrease of the Nv(Podo/Glom) vs. 
sham operated controls. The Nv(Podo/Glom) of uninephrectomized and sham operated 
transgenic mice did not differ. The Nv(Podo/Glom) significantly decreased from 1 to 6 
months of age in both uninephrectomized wild-type and transgenic mice (Fig. 4.16). 
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Fig. 4.16. Numerical volume density of podocytes in glomeruli of sham operated 
(sham) and uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 1 and 
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6 months of age; Data represent means and SEM; Different superscripts indicate significant 
differences between groups (p<0.05). Data at 1 month of age represent numerical volume densities of 
podocytes of the removed left kidney, data of uninephrectomized animals at 6 months of age are 
numerical volume densities of podocytes of the right kidneys obtained from the same animals. 
 
4.8.5 Total number and mean volume of podocytes  
 
The total number of podocytes per glomerulus did not differ between the groups (Fig 
4.17) 
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Fig. 4.17. Number of podocytes per glomerulus of sham operated (sham) and 
uninephrectomized (unx) transgenic (tg) and wild-type (wt) mice at 1 and 6 months of 
age; Data represent means and SEM; Different superscripts indicate significant differences between 
groups (p<0.05). Data at 1 month of age represent podocyte numbers of the removed left kidney, data 
of uninephrectomized animals at 6 months of age are podocyte numbers of the right kidneys obtained 
from the same animals. 
  
 
The mean podocyte volume of 1-month-old transgenic and control mice did not differ. 
At 6 months of age, transgenic mice exhibited a significantly higher mean podocyte 
volume (podocyte hypertrophy) vs. the respective control mice. The mean podocyte 
volume of uninephrectomized wild-type mice was slightly higher than that of sham 
operated controls, but significantly lower than that of sham operated transgenic mice. 
Uninephrectomy did not lead to a significant increase of the mean podocyte volume 
of transgenic vs. sham operated transgenic mice (Fig. 4.18) 
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Fig. 4.18. Mean podocyte volume of sham operated (sham) and uninephrectomized 
(unx) transgenic (tg) and wild-type (wt) mice at 1 and 6 months of age; Data represent 
means and SEM; Different superscripts indicate significant differences between groups (p<0.05). Data 
at 1 month of age represent mean podocyte volumes of the removed left kidney, data of 
uninephrectomized animals at 6 months of age are mean podocyte volumes of the right kidneys 
obtained from the same animals. 
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5. Discussion 
GIPRdn transgenic mice were primarily designed in order to investigate the 
importance of the GIP (glucose dependent insulinotropic polypeptide) / GIP receptor 
axis for the enteroinsular axis in vivo. For this purpose, other mouse models had 
been generated before by means of gene targeting, including GIPR-/- mice and 
glucagon-like-peptide-1 receptor knockout (GLP-1R-/-) mice, which both displayed 
only modest alterations in glucose homeostasis (Miyawaki et al., 1999, Scrocchi et 
al., 1996). The same was true for double mutant mice (GIPR-/-/GLP-1R-/-) (Hansotia 
et al., 2002, Preitner et al., 2002). A potential explanation for these unexpectedly mild 
phenotypic consequences was suggested to be compensation through other factors 
contributing to glucose homeostasis or the more complex alterations resulting from 
the knockout of incretin hormone receptors in all tissues (Baggio et al., 2000, Lewis 
et al., 2000, Pederson et al., 1998). To avoid these complicating mechanisms, the 
expression of a dominant negative mutant of the GIPR in transgenic mice was 
chosen as an alternative strategy to elucidate the role of the GIP receptor within the 
enteroinsular axis in vivo (Herbach et al., 2005, Volz 1997). The cDNA of the human 
GIPR was mutated at the third intracellular loop, where a deletion of eight amino 
acids (pos. 319-326) and a point mutation at position 340 was introduced. The loss of 
function of the mutated GIPR was demonstrated in vitro, using stably transfected 
CHL (Chinese hamster lung) cells: the GIPRdn bound GIP with normal affinity but 
failed to increase intracellular cAMP levels. Transgenic mice were then generated, 
expressing the mutated human GIPR cDNA under the control of the rat pro-insulin 2 
gene promoter in pancreatic β-cells. These GIPRdn transgenic mice demonstrated a 
disturbed development of the endocrine pancreas and showed severe diabetes 
mellitus (Herbach et al., 2005). 
Diabetic nephropathy is one of the most feared diabetes-associated complications in 
humans but its pathogenesis is largely unknown. Analyzing the progression to 
advanced diabetic nephropathy is limited by the lack of appropriate animal models of 
advanced diabetic nephropathy. The mouse is particularly attractive for this sort of 
human disease modeling because of its tractability for genetic manipulation (Gurley 
et al., 2009). GIPRdn transgenic mice have recently been shown to exhibit diabetes-
associated kidney lesions that resemble early and intermediate stages of human 
diabetic kidney disease (Herbach et al., 2009). In addition, necropsy of a GIPRdn 
transgenic mouse by coincidence revealed unilateral renal agenesia. The remaining 
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kidney of this animal showed advanced diabetes-associated glomerular and tubulo-
interstital lesions that seemed more severe than kidney alterations of GIPRdn 
transgenic animals investigated so far. This unintentional finding evoked the question 
if these severe and advanced kidney alterations would be reproducible by performing 
unilateral uninephrectomy early in life in these transgenic mice (Wanke and Herbach, 
personal communication). 
The aim of the present study was to characterize clinical and pathomorphological 
effects of uninephrectomy on diabetes-associated kidney lesions of GIPRdn 
transgenic diabetic mice. It was hypothesized, according to the unique renal findings 
in the one GIPRdn transgenic mouse exhibiting unilateral renal agenesia, that 
uninephrectomy would aggravate the development of diabetic nephropathy in six- 
and twelve-month-old GIPRdn transgenic mice, vs. sham operated transgenic and 
wild-type control mice. Nagata et al. showed in 1992 that uninephrectomy in young 
rats results in a higher incidence of glomerulosclerosis than in adults. The reason for 
this higher susceptibility in young animals is not fully understood, but this does 
suggest that uninephrectomy in young animals may represent a particularly 
promising model in which to study the development of advanced nephropathy 
(Nagata et al., 1992). Therefore, uninephrectomy was undertaken in 1-month-old 
male GIPRdn transgenic diabetic mice.  
 
In vivo findings 
At 21 days of age, blood glucose levels were significantly elevated in transgenic 
animals and there was no difference in glucose concentrations between transgenic 
groups that were chosen for future uninephrectomy or sham operation. The finding of 
early onset diabetes is in line with the results of Herbach et al. (2005) who found the 
onset of diabetes mellitus in GIPRdn transgenic mice to occur with the beginning 
intake of rodent chow, between 14 and 21 days of age (Herbach et al., 2005). The 
diabetic phenotype was further affirmed in the present study by measurement of 
serum glucose levels of four-, six-, and twelve-month-old mice. Serum glucose levels 
of transgenic mice were largely higher than those of wild-type mice, irrespective of 
the age at sampling. Uninephrectomy had no influence on serum glucose 
concentrations of either transgenic or wild-type mice, suggesting that a reduction of 
renal mass, i.e. uninephrectomy, has no effect on the diabetic state itself. This 
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observation is in line with findings in other diabetic remnant kidney models, e.g. the 
db/db mouse (Ninichuk et al., 2007). 
 
Starting at about 2 months of age, the body weight of diabetic GIPRdn transgenic 
animals was significantly lower than that of control mice. This finding is in 
coincidence with previous studies, using GIPRdn transgenic mice (Herbach et al., 
2005, Herbach et al., 2008). It was shown recently, that the reduced body weight of 
the transgenic animals was mainly due to the reduction of the weight of skin, carcass 
and abdominal fatty tissue, changes that were suggested to result from absolute 
insulin deficiency and disturbed lipogenesis (Herbach 2002, Herbach et al., 2008). 
This finding is in contrast to the situation in human diabetes mellitus, where 
accumulation of fat in the abdomen is a typical finding. Abdominal visceral fat is 
thought to be involved in glucose regulation and to potentiate the development of 
diabetes more than does subcutaneous fat (Resnick and Howard 2004). 
Uninephrectomy had no influence on body-weights of either transgenic or control 
mice. 
 
In humans, considerable evidence of the increased prevalence of hypertension in 
diabetic persons suggests that these two common chronic diseases frequently 
coexist, adding significantly to each others overall morbidity and mortality (Sowers et 
al., 2001). Therefore, blood pressure was determined non-invasively at 2 and 6 
months of age. Both the systolic and diastolic blood pressure did not differ between 
the groups irrespective of the age investigated. Also, uninephrectomy had no 
influence on blood pressure of transgenic or wild-type control mice. Our results are in 
contrast to the findings in human patients suffering from diabetic nephropathy, which 
frequently exhibit hypertension. Hypertension is about twice as frequent in individuals 
with diabetes as in those without. Diabetes mellitus and hypertension are interrelated 
diseases that strongly predispose an individual to atherosclerotic cardiovascular 
disease. In 2003–2004, 75% of adult diabetic patients exhibited blood pressure 
greater than or equal to 130/80 mmHg, or used prescription medications for 
hypertension (ADA 2007). Diabetic nephropathy is an important contributing factor to 
the development of hypertension in the diabetic individual. The high blood pressure 
associated with diabetic nephropathy is usually characterized by sodium and fluid 
retention and increased peripheral vascular resistance (Sowers and Epstein 1995). 
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Other studies, using experimental animals, e.g. streptozotocin-, diet-induced or 
genetically altered diabetic mice (Breyer et al., 2005), however, do not develop 
hypertension, which is in line with results from the present study. Blood pressure 
tends to be reduced in most strains of streptozotocin-treated or diet-induced diabetic 
mice when significant hyperglycemia is present. Blood pressure does not seem to be 
dramatically affected by diabetes in genetically altered mice that are treated with 
streptozotocin, either (Breyer et al., 2005, Gurley et al., 2009). The explanation of this 
difference in blood pressure between diabetic mice and men remains a matter of 
debate. A recent study revealed that some rodent models are resistant to 
arteriosclerotic changes in coronary artery and spontaneous ischemia, which exist in 
many humans with diabetes mellitus (Kawada et al., 2010). In another recent study, 
researchers demonstrated that mice missing the gene „Junb“ which regulates arterial 
contraction capacity, cellular contractility, and motility, don’t become hypertensive 
(Licht et al., 2010).  
 
Serum parameters determined in the present study included important markers for 
renal lesions (urea, creatinine, albumin, total protein) and metabolism (glucose 
(discussed above), triglycerides). Serum urea and creatinine were both elevated in 
uninephrectomized and sham operated GIPRdn transgenic mice. This azotemia was 
not associated with clinical signs of renal failure and may therefore be due to severe 
diabetes-associated polyuria, resulting in sodium-chloride loss and dehydration, 
leading to the so-called hyponatremic syndrome/ chloropenic azotemia (Hepp and 
Häring 1999). Further, an increase in hepatic proteolysis due to insulin deficiency 
results in an increase of urea synthesis and may thereby increase serum urea levels 
(Hepp and Häring 1999, Janka et al., 1999). Another reason for the occurrence of 
azotemia in GIPRdn transgenic mice could be the decreased glomerular filtration due 
to advanced kidney changes and therefore, compensated retention of urinary 
excreted substances. In this study, the GFR of uninephrectomized and sham 
operated transgenic mice was actually reduced and the ACR was increased vs. the 
respective wild-type mice, therefore, diabetic kidney disease may contribute to 
azotemia in GIPRdn transgenic mice. 
The slightly to significantly reduced total protein and albumin serum levels of 
transgenic animals may result from protein catabolism and/ or renal loss of proteins 
(Hepp and Häring 1999). Once GFR markedly decreases, the selectivity of 
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proteinuria disappears and both albumin and other macro-proteins appear in the 
urine in excessive amounts (Reddi and Camerini-Davalos 1990). It could be shown in 
this study, that the GFR is reduced and the ACR is increased in transgenic vs. wild-
type mice, therefore, renal loss of proteins may be responsible for the reduced total 
protein and albumin serum levels. However, the reduced serum protein levels may 
also be secondary to insulin deficient diabetes mellitus of GIPRdn transgenic mice. 
Glucose uptake in muscles is insulin dependent and therefore reduced in insulin-
deficient diabetes. Further, the amino acid uptake and protein synthesis is disturbed 
and proteolysis increased. Despite increased supply of free fatty acids, the insulin 
deficiency results in a catabolism of muscular tissue.  
 
The glomerular filtration rate (GFR) is an important parameter for kidney function. At 
time of diagnosis of diabetes mellitus, human patients usually show renal 
hyperfunction and an increased GFR. With onset of microalbuminuria, the GFR 
returns to normal and when macroalbuminuria (albumin excretion more than 10-fold 
increased) is present, the GFR starts to decrease progressively (Mogensen et al., 
1995). Both uninephrectomized and sham operated GIPRdn transgenic mice showed 
a reduced GFR and macroalbuminuria (see below). Uninephrectomy in transgenic 
mice led to a significantly lower GFR than sham operation and a significantly higher 
ACR. In wild-type mice, uninephrectomy did not influence the GFR or ACR. These 
findings suggest that glomerular injury, that accompanies the development of clinical 
nephropathy, is largely responsible for the reduction in GFR of transgenic mice 
(Marshall 2005). This is in agreement with previous studies in which total GFR in 
uninephrectomized male Sprague-Dawley rats was significantly lower than total GFR 
in sham-operated animals at 3 to 6 months after surgery (Nagata et al., 1992). 
Similar results were achieved in male Wistar rats that underwent 5/6 nephrectomy, a 
model of chronic renal failure, where the GFR of these subtotally nephrectomized 
rats was significantly lower than the GFR of control rats (Sviglerova et al., 2010). In 
contrast, the GFR in Akita diabetic mice was significantly increased compared with 
their respective non-diabetic, wild-type controls (Gurley et al., 2009), as observed in 
the stage of renal hyperfunction in human diabetic subjects (Mogensen et al., 1995).  
It has to be mentioned that the GFR calculated in this study has to be interpreted 
carefully, since the Jaffé method was used to determine serum creatinine. New 
methods to accurately measure plasma creatinine by high performance liquid 
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chromatography (HPLC) have been established and have confirmed significant 
overestimation of plasma creatinine using Jaffé alkaline picrate-based methods. In 
mice with normal renal function, the picric acid–based method routinely 
overestimates HPLC-determined serum creatinine by two- to fivefold. When 
compared with inulin clearance, creatinine clearance determinations, using the Jaffé 
reaction underestimates GFR by >50% (Breyer et al., 2005). However, it has not 
been analyzed whether diabetes in mice influences serum creatinine results 
determined by Jaffé method. In humans, ketoacidosis is known to influence serum 
creatinine, using Jaffé method but since GIPRdn transgenic mice do not show 
ketoacidosis, it is likely that serum creatinine levels of both transgenic and wild-type 
mice in this study were overestimated by approximately the same degree (Brosius et 
al., 2009). 
Urine analyses were performed to further analyze renal function and clinical features 
of kidney disease. Urinary creatinine levels of transgenic mice were significantly 
lower than those of wild-type mice, shortly after diabetes onset, which is a common 
finding in uncontrolled diabetes, e.g. in GIPRdn transgenic mice (Herbach et al., 
2009). Uninephrectomy did not influence this parameter in either transgenic or wild-
type mice. Both uninephrectomized and sham operated GIPRdn transgenic mice, 
exhibited a higher ACR as well as higher ACR in 24 hour urine samples than their 
corresponding wild-type control mice. The ACR in spot urine samples of sham 
operated transgenic mice was increased up to 3-fold, whereas that of 
uninephrectomized transgenic mice was increased up to 92-fold vs. the respective 
wild-type controls. The ACR in 24 hour urine samples of sham operated transgenic 
mice was increased 73-fold, that of uninephrectomized transgenic mice was 
increased 400-fold vs. the respective wild-type controls, which, with regard to the 
staging in humans (Mogensen et al., 1995), indicates macroalbuminuria/insipient 
nephropathy in GIPRdn transgenic mice,. According to Breyer et al., a 10-fold 
increase in the ACR may be regarded as abnormal albuminuria and an increase in 
the ACR between 100-1000-fold was suggested to reflect established diabetic renal 
disease in diabetic mouse models (Breyer et al., 2005). Therefore, both 
uninephrectomized and sham operated GIPRdn transgenic mice show clinical signs of 
diabetic kidney disease. Comparable large increases in albuminuria were rarely 
observed in studies using diabetic mice. In the KK-Ay mouse fed a high-cholesterol 
diet, a 1000-fold increased albuminuria was suggested, but not in the Akita mouse 
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bearing an Ins2C96Y mutation or the diabetic eNOS knockout mouse (Breyer et al., 
2005, Gurley et al., 2009, Mohan et al., 2008). However, the NONcNZO mouse 
develops significant and progressively increasing albuminuria, with urine albumin-
creatinine ratios >1000g/mg after 1 year of age (Brosius et al., 2009). Additionally, 
uninephrectomy vs. sham operation in GIPRdn transgenic mice provoked an about 
10-fold increased ACR in both spot urine and 24 hour urine samples. In contrast, the 
ACR of spot urine samples and the ACR in 24 hour urine samples of 
uninephrectomized wild-type mice was unchanged vs. sham operated wild-type mice. 
 
In summary, the clinical results, including increased serum concentrations of 
creatinine and urea, decreased urinary creatinine and GFR, and higher ACR of 
GIPRdn transgenic mice, are the typical biochemical signs of chronic kidney disease 
(Sviglerova et al., 2010). In respect of these findings it can be suggested, that 
uninephrectomy in GIPRdn transgenic mice aggravates the onset and severity of 
kidney damage. 
 
Morphological findings 
Functional markers of chronic renal failure were associated with morphological 
changes in the remnant kidney in studies, using 5/6 nephrectomized Wistar male rats 
(Sviglerova et al., 2010). Since the ACR and GFR of uninephrectomized GIPRdn 
transgenic mice was higher than that of sham operated transgenic animals, the 
development of aggravated kidney lesions was expected in uninephrectomized vs. 
sham operated GIPRdn transgenic mice. 
 
At six months of age, both uninephrectomized and sham operated GIPRdn transgenic 
mice, exhibited a greater kidney volume than the respective wild-type animals. Renal 
hypertrophy generally is a characteristic change in early stages of human diabetes 
(Schwieger and Fine 1990) and various rodent models of diabetes, e.g. GIPRdn 
transgenic mice (Herbach et al., 2009), the BTBR ob/ob mouse, the KK-Ay mouse 
and the NONcNZO mouse, and streptozozocin diabetic mice and rats (Brosius et al., 
2009, Kakoki et al., 2004, Rees and Alcolado 2005). Studies in animals revealed that 
this renal enlargement is mostly due to a combination of tubular hypertrophy and 
hyperplasia and interstitial expansion (Bilous 2001). 
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Both GIPRdn transgenic and wild-type mice that were uninephrectomized exhibited 
increased kidney volumes as compared to their sham operated counterparts. 
Compensatory renal growth is an adaptive response to the loss of renal mass, as 
shown in studies, using uninephrectomized Wistar rats, Sprague-Dawley rats, and 
C57Bl/6 mice, which exhibited increased kidney volumes as compared to their sham 
operated counterparts (Liu and Preisig 2002, Okada et al., 2010, Sviglerova et al., 
2010). 
 
The kidney volumes of 12-month-old uninephrectomized wild-type mice were 
significantly higher than those of age-matched sham operated controls. However, 
there were no differences in the kidney volumes of transgenic mice as opposed to 
controls or between the transgenic uninephrectomized and sham operated groups at 
12 months of age. According to a study in uninephrectomized rats, persistent 
proteinuria causes apoptosis in tubular cells. Apoptosis (programmed cell death) is a 
gene-regulated process that is recognized to play an important role in maintaining 
cell number homeostasis both in health and disease. Unregulated excessive 
apoptosis can contribute to renal damage by depletion of glomerular and 
tubulointerstitial cells, characteristic of progressive chronic nephropathies (Tejera et 
al., 2004). Since uninephrectomized GIPRdn transgenic mice exhibited pronounced 
albuminuria, enhanced apoptosis might explain the lower kidney volumes of 12-
month-old vs. 6-month-old transgenic mice. The findings in GIPRdn transgenic mice 
are in coincidence with findings in human patients, where in early stages of diabetes 
mellitus, the kidneys are enlarged (Bilous 2001). However, later in the course of the 
disease in humans, small kidneys with a granular surface are frequently observed 
(Heptinstall 1991), a finding we could only demonstrate in one uninephrectomized 
GIPRdn transgenic mouse at 7 months of age (see below).  
 
Histologically, the glomeruli of uninephrectomized and sham operated GIPRdn 
transgenic mice at six and twelve months of age showed mesangial expansion, focal 
segmental, sometimes panglomerular glomerulosclerosis, adhesions between the 
glomerular tuft and the capsule of Bowman, and large distorted capillaries. 
Tubulointerstitial lesions of transgenic mice included protein reabsorption droplets in 
proximal tubular epithelia, proteinaceous casts in distal tubules, focal tubular atrophy 
and few focal interstitial mononuclear inflammatory cell-infiltrates. These findings are 
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in coincidence with observations in a previous study, where glomerular damage was 
prominent in GIPRdn transgenic mice, including advanced glomerulosclerosis, 
tubulointerstitial lesions and proteinuria (Herbach et al., 2009). Early uninephrectomy 
aggravated the development of glomerular and tubulo-interstitial lesions in transgenic 
mice of the present study vs. sham operated animals in an age-related manner (e.g. 
diffuse segmental and frequently also panglomerular glomerulosclerosis was 
evident), consistent with the histopathological abnormalities of advanced diabetic 
nephropathy in humans. These pathological changes seen in the human diabetic 
kidney at an advanced point of disease are tubular loss accompanied by glomerular 
and vascular sclerosis. The tubules undergoing atrophy show thickened basement 
membranes. The interstitial tissue is fibrotic and contains inflammatory cells 
(Heptinstall 1991, Tervaert et al., 2010). A previous study in db/db mice showed that 
global glomerulosclerosis at 6 months of age was more common in 
uninephrectomized vs. sham operated db/db mice, where only minor glomerular 
changes were observed. Additionally, early uninephrectomy significantly enhanced all 
markers of tubulo-interstitial injury as compared to sham-operated db/db mice 
(Ninichuk et al., 2007).  
One uninephrectomised GIPRdn transgenic mouse was euthanized at 7 months of 
age due to reduced general condition, loss of body weight and signs of anemia. The 
remnant kidney was smaller than that of all other transgenic animals and exhibited a 
granular surface, indicating chronic nephropathy. Glomerulosclerotic lesions were 
evident in a diffuse panglomerular manner and this animal exhibited cystic dilation of 
many tubules, hyaline casts in distal tubules, tubular atrophy, vast interstitial fibrosis 
and focal mononuclear cell infiltration. The macroscopic and histologic appearance of 
the kidney of this 7-month-old animal led to the diagnosis of end-stage renal disease. 
This is the first observation of terminal renal failure in a mouse model of diabetic 
kidney disease. 
 
Glomerular changes due to diabetes or uninephrectomy were investigated, using 
quantitative stereological methods in GIPRdn transgenic and wild-type mice. The 
mean glomerular volume was significantly increased in 6-month-old 
uninephrectomized and sham operated transgenic mice vs. controls. This finding is in 
coincidence with previous observations in GIPRdn transgenic mice (Herbach et al., 
2009). Up to 8 weeks of age, the mean glomerular volume of male transgenic mice 
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was not yet increased vs. male controls. After that, a progressive increase in the 
mean glomerular volume was observed in both male and female transgenic mice 
(Herbach et al., 2009). Glomerular hypertrophy is observed in various diabetic animal 
models. By 18–20 months of age, glomerular enlargement and mesangial matrix 
expansion become obvious in the db/db mouse (Sharma et al., 2003), the BTBR 
ob/ob mouse (Hudkins et al., 2010), and streptozotocin-induced diabetic mice 
(Mizuno et al., 2004). The current investigation also showed a significant increase in 
the mean glomerular volume of uninephrectomized compared to sham operated 
GIPRdn transgenic as well as uninephrectomized vs. sham operated wild-type mice at 
6 months of age. Glomeruli of uninephrectomized wild-type and sham operated 
transgenic animals showed an equal mean glomerular volume, showing that 
uninephrectomy in healthy animals leads to the same extent of glomerular 
hypertrophy as hyperglycemia. In a remnant kidney mouse model (5/6 nephrectomy) 
without diabetes, a 40% increase in glomerular tuft area was observed vs. sham 
operated mice (Nakayama et al., 2009), a similar increase as of the mean glomerular 
area of GIPRdn transgenic diabetic vs. non-diabetic control animals (data not shown). 
Uninephrectomy in young male Sprague-Dawley rats also caused increased 
glomerular tuft growth compared to sham operated controls. Along with the 
hypertrophic growth of glomeruli in uninephrectomized rats, several kinds of 
structural changes were observed increasing in frequency and severity with time. 
These uninephrectomy enforced alterations in the Sprague-Dawley rat are seen in 
changes in the width and shape of glomerular capillaries associated with changes in 
the distribution of the associated mesangium, in various changes in the podocyte 
structure; and in tuft adhesions to Bowman's capsule (Nagata and Kriz 1992), similar 
changes that were observed in GIPRdn transgenic mice investigated the present 
study. 
 
As a consequence of glomerular hypertrophy, the mean glomerular mesangium and 
capillary volumes were significantly increased in both uninephrectomized and sham 
operated GIPRdn transgenic mice vs. controls, despite unchanged volume fractions of 
mesangium and capillaries.  
The mean glomerular mesangium and capillary volumes
 
increased significantly in 
both uninephrectomized wild-type and transgenic animals from 1 to 6 months of age, 
but this increase was more pronounced in uninephrectomized transgenic mice. 
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The most characteristic and clinically important glomerular lesion in human diabetes 
mellitus is mesangial expansion. The mesangial volume fraction (Vv(mes/glom)) was the 
main structural predictor of the rate of decline in GFR and albuminuria, whereby a 
large Vv(mes/glom) was associated with increased albuminuria and loss in GFR 
(Christensen et al., 2001). In a study by Østerby et al. (1993) in humans, the renal 
lesions were examined, using a glomerulopathy index, combining the basement 
membrane thickness and Vv(mes/glom). It was shown that there is a relationship 
between the course of kidney function and the glomerulopathy index (Osterby et al., 
1993). A pathophysiological study also demonstrated that the relationship between 
Vv(mes/glom) and rate of decline in GFR in human patients probably results from the 
expanding mesangium, compromising the structure of glomerular capillaries and 
reducing the ultrafiltration coefficient filtration (defined as the product of effective 
hydraulic permeability and total glomerular capillary surface area of the kidney) 
(Christensen et al., 2001). Mesangial matrix fraction increases are frequently found in 
diabetic animals, such as db/db, BTBR ob/ob, and streptozotocin treated mice and 
also rats vs. non-diabetic controls (Chen et al., 2003, Hudkins et al., 2010, Melhem et 
al., 2002, Mizuno et al., 2004).  
The numerical volume density of podocytes in glomeruli of 6-month-old transgenic 
mice was significantly lower than that of the respective wild-type mice. This finding is 
in line with a previous study, where the numerical volume density of podocytes in 
glomeruli was significantly reduced in both 8-week-old male and female GIPRdn 
transgenic mice (Herbach et al., 2009). Della Vestra et al. suggested that the 
numerical volume density of podocytes is functionally more relevant than absolute 
numbers in type 2 diabetic patients, since the numerical volume density of podocytes 
but not absolute numbers is inversely related to albumin excretion rate. Podocytes in 
enlarged glomeruli have to cover a larger glomerular basement membrane area and 
are subjected to increased mechanical stress and injury. Widening of foot processes 
and increased albumin excretion, loss of podocytes and glomerulosclerosis are the 
consequences (Dalla Vestra et al., 2003). However, in the present study only the 
mean glomerular volume (and consequently the mean mesangial and capillary 
volumes) was altered significantly more in uninephrectomized than in sham operated 
transgenic mice but the numerical volume density of podocytes was equal despite 
large difference in the ACR in spot urine samples. It therefore seems likely that the 
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numerical volume density of podocytes may not be a good predictor for severity of 
albuminuria in GIPRdn transgenic mice. 
 
The number of podocytes was not altered in GIPRdn transgenic mice analyzed in the 
present and a previous study (Herbach et al., 2009). In a different study in OVE26 
diabetic mice, Teiken et al. (2007) documented a substantial reduction of the mean 
podocyte number per glomerulus between 150 days and 450 days of age, suggesting 
that podocyte loss could also be an age-related matter (Teiken et al., 2008). In 
diabetic ob/ob mice on the black and tan, brachyuric genetic background (BTBR 
ob/ob mice), the number of podocytes was stated to be reduced early in the disease 
course vs. wild-type mice and a loss of podocytes was postulated. However, the 
number of podocytes per glomerulus was not determined using state of the art 
quantitative-stereological techniques, and in addition, podocyte number of 8- and 20-
week old BTBR ob/ob mice was essentially the same, arguing against podocyte loss. 
Further, there was no increase in the number of apoptotic podocytes in the BTBR 
ob/ob mice at either early or late time points compared with wild-type littermates 
(Hudkins et al., 2010). The podocyte density, however, was significantly reduced in 
BTBR ob/ob mice compared with BTBR WT mice at every time point studied and this 
diminished podocyte density occurred in conjunction with increased glomerular 
volumes in BTBR ob/ob vs. BTBR WT mice (Hudkins et al., 2010), similar to GIPRdn 
transgenic mice. Likewise, in male Sprague-Dawley rats, the average number of 
podocytes per glomerulus changed neither in control animals, nor after 
uninephrectomy. Due to the increase in tuft volume and the unaltered podocyte 
number, the numerical density of podocytes decreased with age in both groups. The 
lowest values were found in the hypertrophied glomeruli of the uninephrectomized 
group. This study in the remnant kidney rat could show that the elaborately shaped 
podocyte is incapable of replication. Remaining podocytes are obliged to grow and to 
extend their foot processes to maintain the area covered (Nagata and Kriz 1992). 
Wanke et al. (2001) demonstrated that podocyte hypertrophy is correlated with 
increasing glomerular volume, leading to severe podocyte stretching, due to the 
podocytes’ inability to proliferate, resulting in detachment of podocytes. These 
podocyte alterations in the growth hormone (GH) transgenic mouse (TM) provide 
evidence that podocyte damage plays a significant role in the pathogenesis of 
progressive nephropathy (Wanke et al., 2001). A loss of podocytes in patients with 
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clinical nephropathy was associated with an increase in the surface area covered by 
each remaining cell and was also accompanied by increases in the volumes of 
remaining podocytes. These findings suggested that podocyte loss contributes to the 
progression of diabetic nephropathy and that these morphological changes may 
relate to the loss of glomerular permselectivity in diabetic nephropathy (Pagtalunan et 
al., 1997). Another study in human patients with diabetic nephropathy showed that 
podocyte loss is correlated with clinical and pathological disease progression (e.g. 
proteinuria and mesangial expansion). Podocyte loss was suggested to show a 
stronger relationship with the renal prognosis than glomerular basement membrane 
thickening or mesangial expansion (Mundel and Shankland 2002). In the present 
study neither uninephrectomised nor sham operated GIPRdn transgenic mice showed 
reduced numbers of podocytes vs. wild-type mice, despite marked albuminuria, 
therefore, the number of podocytes does not seem to be related to the development 
of albuminuria in GIPRdn transgenic mice.  
 
At 6 months of age, transgenic mice exhibited a significantly higher mean podocyte 
volume (podocyte hypertrophy) vs. the respective control mice. This finding is in 
coincidence with a previous study where it was shown that in male GIPRdn transgenic 
mice, podocyte hypertrophy occurred even before glomerular hypertrophy was 
evident, and without changes in blood pressure (Herbach et al., 2009). Therefore, it 
was concluded that hyperglycemia directly influenced glomerular epithelial cell 
growth in early disease stages in GIPRdn transgenic mice. Adaptive growth of the 
podocytes due to glomerular hypertrophy (Wiggins et al., 2005) may further 
contribute to podocyte growth in later stages of the disease, as analyzed in the 
present study. However, in 6-month-old uninephrectomized wild-type mice, the 
podocyte volume was only slightly but not significantly higher than that of sham 
operated controls, despite significantly higher mean glomerular volume, and the 
mean podocyte volume of sham operated transgenic mice was significantly higher 
than that of uninephrectomized wild-type mice despite equal mean glomerular 
volumes. In addition, podocytes of both sham operated and uninephrectomized 
transgenic mice were equally sized, although the mean glomerular volumes were 
significantly different. All these observations argue for a more pronounced impact of 
hyperglycemia on podocyte growth than adaptive growth. 
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Hypertrophy of renal cells is thought to contribute to diabetes associated kidney 
lesions, such as glomerulosclerosis, tubular atrophy and interstitial fibrosis, which 
was also observed in the present study. Podocyte hypertrophy, caused by high 
glucose concentrations, may eventually lead to podocyte loss and glomerulosclerosis 
(Gross et al., 2003, Kim 2005).  
 
Reduction of renal mass does not uniformly accelerate the progression of kidney 
disease in humans or mice (Zeier et al., 1992) However, a reduction of renal mass 
can particularly accelerate the progression of glomerulopathies probably by 
enhancing glomerular hyperfiltration (Ritz 2006). Uninephrectomy may be a preferred 
method of accelerating diabetic nephropathy in GIPRdn transgenic mice because it 
does not affect unrelated or other pathomechanisms of diabetic nephropathy. Our 
data shows that e.g. body weight, blood and serum glucose concentrations, urine 
creatinine, ACR, GFR and mean glomerular capillary volume were not affected by 
surgery in wild-type mice. The remnant kidneys of early uninephrectomized GIPRdn 
transgenic diabetic mice resemble the changes seen in humans with diabetic kidney 
disease. This model shows a high degree of reproducibility with a minimum of 
undesirable side-effects. Thus, uninephrectomized GIPRdn transgenic mice represent 
a useful tool in the study of advanced diabetes-associated kidney changes. 
Together, we conclude that uninephrectomy performed at 4 weeks of age aggravates 
the development of diabetes-associated kidney lesions in male GIPRdn transgenic 
mice. This model may be instrumental for validating targets potentially involved in the 
progression of diabetic renal disease.  
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6. Summary 
Clinical and pathomorphological characterization of uninephrectomized GIPRdn 
transgenic diabetic mice  
 
Diabetic nephropathy is one of the leading causes of end-stage renal disease in 
humans, however, the pathogenesis of this feared diabetes-associated complication 
is far from being understood. Diabetic animal models are used to study the 
pathogenesis of diabetic nephropathy but the existing experimental animals develop 
kidney lesions that closely resemble those observed in human patients only in the 
early stages. The aim of this study was to analyze whether uninephrectomy is 
capable of aggravating the diabetes-associated kidney lesions in GIPRdn transgenic 
mice, a novel animal model for diabetic renal disease.  
GIPRdn transgenic and wild-type control mice either underwent uninephrectomy or 
sham operation at 1 month of age. In vivo investigations included the determination 
of body weights, blood pressure, blood glucose, serum urea, creatinine, total protein, 
albumin, triglyceride, and chloride levels. The urine albumin and creatinine 
concentrations were determined in regularly taken spot urine samples and the 
albumin to creatinine ratio (ACR) was calculated. The ACR in 24 hour urine samples 
as well as the glomerular filtration rate (GFR) were calculated at 4 months of age. 
Histological and quantitative stereological analyses of the kidneys were performed, 
using 6- and 12-month-old animals. The mean glomerular volume, mean glomerular 
mesangium and capillary volume, the numerical volume density of podocytes in 
glomeruli, and the number and mean size of podocytes were estimated.  
At weaning (21 days), all transgenic animals already exhibited severe hyperglycemia 
and from 2 months of age onwards, transgenic mice weighed less than wild-type 
mice. Uninephrectomy did not influence blood glucose or body weights of either 
GIPRdn transgenic or wild-type mice vs. sham operated animals. Neither diabetes nor 
uninephrectomy had an impact on blood pressure in the examined groups. Between 
one and two months of age, GIPRdn transgenic mice showed reduced urine 
creatinine levels, and from 2 months of age onwards, their ACR was significantly 
increased vs. wild-type mice. Uninephrectomy had no influence on urine creatinine, 
ACR and GFR of wild-type mice vs. sham operated wild-types. In transgenic mice, 
urine creatinine was also not influenced by uninephrectomy, but the ACR was 
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significantly higher and GFR was significantly lower in uninephrectomized than in 
sham operated transgenic mice.  
Histologically, glomeruli of transgenic mice showed focal segmental to panglomerular 
glomerulosclerosis, synechia between the glomerular tuft and the capsule of 
Bowman, and large distorted capillaries. Tubulo-interstitial lesions of transgenic mice 
included tubular atrophy, proteinaceous casts in distal tubules, focal interstitial 
fibrosis and mononuclear cell infiltration. The severity of these renal lesions 
progressed in an age-related manner and was enhanced by uninephrectomy in 
transgenic mice. One uninephrectomized transgenic animal exhibited renal features 
of end-stage kidney disease at 7 months of age. Wild-type mice occasionally showed 
mild kidney lesions, which also deteriorated slightly in an age-related manner but 
were never as pronounced as in transgenic animals. The kidney volume, mean 
glomerular volume and mean glomerular mesangium volume of 6-month-old 
transgenic mice was significantly increased vs. wild-type mice and uninephrectomy 
led to significantly enhanced kidney and glomerular growth, as well as mesangial 
expansion in both transgenic and wild-type mice vs. their sham operated counter 
parts.  
The numerical volume density of podocytes was significantly decreased and the 
mean podocyte volume was significantly increased in transgenic vs. wild-type mice. 
Uninephrectomy did not influence these two parameters of either transgenic or wild-
type mice vs. their sham operated counterparts.  
In summary, early uninephrectomy aggravates clinical and pathomorphological 
features of chronic renal disease in GIPRdn transgenic mice. Therefore, 
uninephrectomized GIPRdn transgenic mice provide a valuable new model for 
studying the pathogenesis of diabetic kidney disease and for testing novel treatment 
strategies. 
 
7. Zusammenfassung 
Klinische und pathomorphologische Charakterisierung unilateral 
nephrektomierter GIPRdn transgener diabetischer Mäuse  
 
Die diabetische Nephropathie ist eine der Hauptursachen des chronischen 
Nierenversagens des Menschen, wobei die Pathogenese dieser gefürchteten 
Diabetes-assoziierten Komplikation bei weitem nicht erforscht ist. Diabetische 
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Tiermodelle werden eingesetzt, um die Pathogenese der diabetischen Nephropathie 
zu untersuchen, jedoch gleichen die Nierenschäden bei den vorhandenen 
Versuchstieren jenen bei humanen Patienten nur in den Frühstadien. Das Ziel dieser 
Studie war es zu untersuchen, ob durch Uninephrektomie die Diabetes-assoziierten 
Nierenveränderungen bei GIPRdn transgenen Mäusen, einem neuartigen Tiermodell 
für diabetische Nephropathie, verstärkt werden können.  
GIPRdn transgene Mäuse und Wildtypmäuse wurden im Alter von 1 Monat entweder 
uninephrektomiert oder scheinoperiert. In vivo Untersuchungen beinhalteten die 
Bestimmung von Körpergewicht, Blutdruck, Blutzucker und die Messung der 
Harnstoff-, Kreatinin-, Gesamtprotein-, Albumin-, Triglyzerid- und 
Chloridkonzentration im Serum. In regelmäßig genommenen Spontanurinproben 
wurden Albumin- und Kreatininkonzentrationen gemessen und das Albumin-
Kreatinin-Verhältnis (ACR) berechnet. Die ACR in den 24 Stunden 
Sammelharnproben sowie die glomeruläre Filtrationsrate (GFR) wurden im Alter von 
4 Monaten bestimmt. Histologische und quantitativ-stereologische Analysen der 
Nieren wurden bei 6- und 12-Monate alten Tieren durchgeführt. Das mittlere 
Glomerulumvolumen, das mittlere glomeruläre Mesangium- und Kapillarvolumen, die 
numerische Volumendichte der Podozyten in den Glomerula, sowie Anzahl und 
mittlere Größe der Podozyten wurden analysiert. 
Beim Absetzen (21 Tage) zeigten alle transgenen Tiere bereits eine schwere 
Hyperglykämie und ab einem Alter von 2 Monaten wogen transgene Mäuse weniger 
als Wildtypmäuse. Die Uninephrektomie hatte keinen Einfluss auf die 
Blutzuckerkonzentration oder das Körpergewicht bei GIPRdn transgenen oder Wildtyp 
Mäusen im Vergleich zu Werten bei scheinoperierten Tieren. Weder der Diabetes 
noch die Uninephrektomie wirkten sich auf den Blutdruck in den verschiedenen 
Mäusegruppen aus. Im Alter von ein bis zwei Monaten waren bei GIPRdn transgenen 
Mäusen die Harnkreatininwerte niedriger und ab einem Alter von 2 Monaten war ihre 
ACR signifikant höher als bei Wildtyp-Mäusen. Die Uninephrektomie hatte keinen 
Einfluss auf Harnkreatinin, ACR und GFR von Wildtypmäusen im Vergleich zu 
Werten bei scheinoperierten Wildtypen. Bei transgenen Mäusen wurde die 
Harnkreatininkonzentration ebenfalls nicht durch die Uninephrektomie beeinflusst, 
aber bei uninephrektomierten transgenen Mäusen war die ACR signifikant höher und 
die GFR signifikant niedriger als bei scheinoperierten transgenen Tieren. 
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Histologisch zeigten die Glomerula von transgenen Mäusen fokal segmentale und 
panglomeruläre Glomerulosklerose, Synechien zwischen dem Glomerulum und der 
Bowman’schen Kapsel und große dilatierte Kapillaren. Tubulointerstitielle Läsionen 
transgener Mäuse beinhalteten Tubulusatrophie, Proteinzylinder in distalen Tubuli, 
fokale interstitielle Fibrose und mononukleäre Zellinfiltrate. Der Schweregrad der 
Nierenschädigung schritt altersabhängig voran und wurde durch die 
Uninephrektomie bei transgenen Mäusen verstärkt. Ein 7 Monate altes 
uninephrektomiertes transgenes Tier zeigte renale Veränderungen im Sinne einer 
terminalen Nephropathie. Wildtypmäuse wiesen nur gelegentlich geringgradige 
Nierenveränderungen auf, die altersassoziiert leicht zunahmen, jedoch bei weitem 
nicht dem Grad der Veränderungen bei transgenen Tieren entsprachen.  
Das Nierenvolumen, das mittlere Glomerulumvolumen und das mittlere glomeruläre 
Mesangiumvolumen 6 Monate alter transgener Mäuse war im Vergleich zu 
Wildtypmäusen signifikant erhöht und durch die Uninephrektomie stieg das renale 
und glomeruläre Wachstum bei transgenen Tieren noch einmal erheblich im 
Vergleich zu scheinoperierten GIPRdn transgenen Mäusen. Ferner führte die 
Uninephrektomie sowohl bei transgenen als auch Wildtypmäusen zur Zunahme des 
mittleren glomerulären Mesangiumvolumens gegenüber entsprechenden 
scheinoperierten Tieren. 
Bei den transgenen Mäusen war die numerische Volumendichte der Podozyten in 
Glomerula deutlich verringert und das mittlere Podozytenvolumen signifikant erhöht 
gegenüber Wildtypmäusen. Die Uninephrektomie hatte weder bei transgenen noch 
bei Wildtyp-Mäusen einen Einfluss auf diese beiden Parameter gegenüber den 
scheinoperierten Pendants. 
Zusammenfassend zeigt die vorliegende Studie, dass die frühzeitige 
Uninephrektomie das klinische und pathomorphologische Erscheinungsbild der 
chronischen Nierenerkrankung bei GIPRdn transgenen Mäusen verstärkt. 
Uninephrektomierte GIPRdn transgene Mäuse bieten daher ein wertvolles neuartiges 
Modell für das Studium der Pathogenese der diabetischen Nierenerkrankung sowie 
zur Erprobung von neuartigen Behandlungsstrategien. 
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9. Attachment 
9.1 Protocol for silver staining of SDS-PAGE gels 
 
 Silver stain for SDS-PAGE gels  
1.) Fixation solution 
99.6 % Ethanol (Roth, Germany) l 
Glacial acetic acid (Sigma, Germany)  
37% Formaldehyde (Roth, Germany)  
ad 1000 ml distilled water 
60 minutes 
500 m 
120 ml 
0.5 ml 
 
2.) Washing in 50 % Ethanol 3 x 20 minutes 
3.) Pre-treatment 
Sodium thiosulphate (Merck, Germany)  
ad 50 ml distilled water 
1 minute 
0.05 g 
4.) Washing in distilled water 3 x 20 seconds 
5.) Impregnation 
Silver nitrate (Roth, Germany) 37% Formaldehyde 
(Roth, Germany)  
ad 50 ml distilled water 
20 minutes 
0.05 g 
35 l 
 
6.) Washing in distilled water 2x 20 seconds 
7.) Develop 
Sodium carbonate (Roth, Germany)  
Sodium thiosulphate (Merck, Germany)  
37% Formaldehyde (Roth, Germany)  
ad 1000 ml distilled water 
until bands become visible 
3 g 
0.2 mg 
50 l 
 
8.) Washing in distilled water 20 seconds 
9.) Stop solution 
0.1 M EDTA (Sigma, Germany)  
 
9.2 Drying of SDS-PAGE gels 
The DryEaseTM Mini-Gel Drying System (DryEase Mini-Gel Dryer Frame, DryEase 
Mini-Gel Drying Base, DryEase Mini Cellophane and Gel-Dry Drying Solution; Novex, 
Germany) was used for drying polyacrylamid gels. Stained gels were washed in 
distilled water 3 times for 2 minutes and then equilibrated in Gel-dry Solution for 15- 
20 minutes on a rotary shaker (Heidolph, Germany). Rough edges of the gel were 
cut off, using a razor blade. 2 pieces of cellophane were pre-wetted in Gel-Drying 
Solution for 15-20 seconds. A DryEase gel drying frame was placed on the gel dryer 
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base and covered with one cellophane piece. The gel was placed in the centre of the 
cellophane sheet; no air was to be trapped between the gel and the cellophane 
sheet. The gel was covered with a second layer of pre-wetted cellophane. No air was 
to be trapped between gel and the cellophane sheets. Wrinkles were removed with a 
gloved hand. The remaining frame was aligned so that its corner pins fit into the 
holes on the bottom frame. Plastic clamps were pushed onto the four edges of the 
frame. The assembly was set upright. Gels were dried for 12-36 
hours; drafts were avoided. The gel/cellophane sandwich was removed and excess 
cellophane was trimmed off. Dried gels were pressed between pages of a book for 
approximately 2 days and then stored in a cassette. 
 
 
Perspective 
 
The glomerular basement membrane thickness should be measured, since this is 
one of the earliest morphological alterations observed in diabetic nephropathy. 
Calculation of the filtration slit frequency (FSF) of the podocyte foot projections 
should also be carried out because a reduced FSF in uninephrectomized transgenic 
mice might explain the higher ACR of these animals vs. sham operated mice.  
 
Since uninephrectomized GIPRdn transgenic diabetic mice serve as a very promising 
model for the study of diabetic nephropathy, clinical studies on novel diabetes 
medication should follow uninephrectomy, e.g. Pioglitazon (used for the treatment of 
type 2 diabetes mellitus), in order to find out if at any time it is possible to intervene 
and/ or reverse the pathological process.  
 
Further research should pick up molecular mechanisms that aggravate the course 
towards advanced glomerular lesions in end-stage kidney diseases of the 
investigated animal model, such as real time PCR of isolated glomeruli to study 
pathogenic factors. 
 
  
98
Acknowledgements 
I would like to thank Prof. Dr. Rüdiger Wanke for giving me the opportunity to perform 
this dissertation. I am extremely grateful for his immense patience and kindness. 
I also wish to express my great gratitude to Dr. Nadja Herbach for her generous help 
in performing this doctorate, her immense support, care, hospitality, guidance, and 
continuous belief in me.  
My special thanks go to Dr. Andreas Blutke, Dr. Lelia van Bürck, Dr. Sabine Kautz, 
Mrs. Marion Schuster, and Mr. Pierre Börjes for their support and friendship.  
Further acknowledgements go to all employees at the Institute of Veterinary 
Pathology for their help, especially to Mrs. Angela Siebert for her always kind and 
helpful attitude and dedicated work, Mrs Lisa Pichl for laboratory assistance at all 
times, Mrs. Beate Schmidt, and Mrs. Marjam O’Gorman for their encouragement and 
company, Mrs. Sabine Zwirz and Mr. Adrian Ciolovan for animal care, Mrs. Heike 
Sperling for performance of plastic histology. A special thank goes to the staff of the 
laboratory of the Clinic for Internal Veterinary Medicine (Head: Prof. Dr. Katrin 
Hartmann) for measurement of the creatinine contents in the urine samples, and to 
the staff of the City Clinic Munich in Schwabing for screening of the serum 
parameters. 
Finally, I am particularly grateful to my loving family, my wonderful husband and my 
dear friends, especially to Elisabeth Albescu, for always being there for me, 
supporting me, and never loosing their faith in me. 
 
  
 
